EP2447266A1 - Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38 - Google Patents

Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38 Download PDF

Info

Publication number
EP2447266A1
EP2447266A1 EP11176338A EP11176338A EP2447266A1 EP 2447266 A1 EP2447266 A1 EP 2447266A1 EP 11176338 A EP11176338 A EP 11176338A EP 11176338 A EP11176338 A EP 11176338A EP 2447266 A1 EP2447266 A1 EP 2447266A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
aryl
optionally substituted
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP11176338A
Other languages
German (de)
English (en)
Other versions
EP2447266B1 (fr
Inventor
Jeffrey C. Boehm
James Francis Callahan
Anthony William James Cooper
Stefano Livia
Neysa Nevins
Beth A. Norton
Zehong Wan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of EP2447266A1 publication Critical patent/EP2447266A1/fr
Application granted granted Critical
Publication of EP2447266B1 publication Critical patent/EP2447266B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to novel compounds and their use as pharmaceuticals, particularly as p38 kinase inhibitors, for the treatment of certain diseases and conditions.
  • Intracellular signal transduction is the means by which cells respond to extracellular stimuli. Regardless of the nature of the cell surface receptor (e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled), protein kinases and phosphatases along with phospholipases are the essential machinery by which the signal is further transmitted within the cell [ Marshall, J. C. Cell, 80, 179-278 (1995 )].
  • the cell surface receptor e. g. protein tyrosine kinase or seven-transmembrane G-protein coupled
  • protein kinases and phosphatases along with phospholipases are the essential machinery by which the signal is further transmitted within the cell [ Marshall, J. C. Cell, 80, 179-278 (1995 )].
  • Protein kinases can be categorized into five classes with the two major classes being tyrosine kinases and serine / threonine kinases, depending upon whether the enzyme phosphorylates its substrate(s) on specific tyrosine(s) or serine / threonine(s) residues [ Hunter, T., Methods in Enzymology (Protein Kinase Classification) p. 3, Hunter, T.; Sefton, B. M.; eds. vol. 200, Academic Press; San Diego, 1991 ].
  • MAPKs mitogen-activated kinases
  • the MAPKs modulate the activity of numerous cell functions such as translocation and activation of transcription factors that control transcription of effector molecules such as cytokines, COX-2, iNOS; the activity of downstream kinases that effect translation of mRNAs; and cell cycle pathways through transcription or modification of enzymes.
  • p38 MAPK pathway refers in most cell types to the isoform p38 ⁇ which is ubiquitously expressed.
  • Extracellular stimuli such as those described above are generated in a number of chronic diseases which are now understood to have a common underlying pathophysiology termed inflammation.
  • An environmental insult or local cell damage activates cellular response pathways, including but not limited to p38; local cells then generate cytokines and chemokines, in turn recruiting lymphocytes such as neutrophils and other granulocytes.
  • lymphocytes such as neutrophils and other granulocytes.
  • the consequences include recruitment of additional lymphocytes such as additional phagocytic cells or cytotoxic T cells, and ultimately the adaptive immune response is initiated through activation of T cells.
  • Atherosclerosis is regarded as a chronic inflammatory disease, which develops in response to injury of the vessel wall and is characterized by the complex development of an occlusive and prothrombotic atheroma.
  • the pathogenesis of this lesion generally involves endothelial dysfunction (reduced bioavailable NO), adhesion molecule expression, adhesion and infiltration of leukocytes, cytokine and growth factor generation, accumulation of foam cells, expansion of extracellular lipid and matrix, activation of matrix metalloproteases (MMPs) and proliferation of vascular smooth muscle cells.
  • endothelial dysfunction reduced bioavailable NO
  • adhesion molecule expression adhesion and infiltration of leukocytes
  • cytokine and growth factor generation accumulation of foam cells
  • expansion of extracellular lipid and matrix activation of matrix metalloproteases (MMPs) and proliferation of vascular smooth muscle cells.
  • MMPs matrix metalloproteases
  • CSBP CSBP
  • p38 the isoforms p38 ⁇ and p38 ⁇ are the targets of the compounds described
  • SK&F 86002 was the prototypic example.
  • These compounds inhibited IL-1 and TNF synthesis in human monocytes at concentrations in the low uM range [ Lee, et al.; Int. J. Immunopharmac. 10(7), 835(1988 )] and exhibited activity in animal models which are refractory to cyclooxygenase inhibitors [ Lee; et al., Annals N. Y. Acad. Sci., 696, 149(1993 )].
  • the mechanism by which stress signals (including bacterial and viral infection, pro-inflammatory cytokines, oxidants, UV light and osmotic stress) activate p38 is through activation of kinases upstream from p38 which in turn phosphorylate p38 at threonine 180 and tyrosine 182 resulting in p38 activation.
  • MAPKAP kinase-2 and MAPKAP kinase-3 have been identified as downstream substrates of CSBP/p38 which in turn phosphorylate heat shock protein Hsp27 and other substrates. Additional downstream substrates known to be phosphorylated by p38 include kinases (Mnk1/2, MSK1/2 and PRAK) and transcription factors (CHOP, MEF2, ATF2 and CREB).
  • p38 kinase inhibitors are effective in a number of different cell types in decreasing the synthesis of a wide variety of pro-inflammatory proteins including, IL-6, IL-8, GM-CSF, RANTES and COX-2.
  • Inhibitors of p38 kinase have also been shown to suppress the TNF-induced expression of VCAM-1 on endothelial cells, the TNF-induced phosphorylation and activation of cytosolic PLA2 and the IL-1-stimulated synthesis of collagenase and stromelysin.
  • Interleukin-1 IL-1
  • Tumor Necrosis Factor TNF
  • IL-1 Tumor Necrosis Factor
  • monocytes a variety of cells
  • macrophages a variety of cells
  • smooth muscle cells IL-1
  • IL-1 has been demonstrated to mediate a variety of biological activities thought to be important in immunoregulation and other physiological conditions such as inflammation [See, e.g., Dinarello et al., Rev. Infect. Disease, 6, 51 (1984 )].
  • the myriad of known biological activities of IL-1 include the activation of T helper cells, induction of fever, stimulation of prostaglandin or collagenase production, neutrophil chemotaxis, induction of acute phase proteins and the suppression of plasma iron levels.
  • TNF production has been implicated in mediating or exacerbating a number of diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic obstructive pulmonary disease, silicosis, pulmonary sarcoisosis, bone resorption diseases, reperfusion injury, graft vs.
  • diseases including rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic obstructive pulmonary disease, silicosis, pulmonary sarcoisosis, bone
  • allograft rejections fever and myalgias due to infection, such as influenza, cachexia secondary to infection or malignancy, cachexia, secondary to acquired immune deficiency syndrome (AIDS), AIDS, ARC (AIDS related complex), keloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, or pyresis.
  • AIDS cachexia secondary to infection or malignancy
  • cachexia secondary to acquired immune deficiency syndrome
  • AIDS AIDS
  • ARC AIDS related complex
  • keloid formation scar tissue formation
  • Crohn's disease Crohn's disease
  • ulcerative colitis or pyresis.
  • Inflammatory diseases are also marked by increases in IL-6 and C-reactive protein (CRP), both of which are sensitive to inhibition by p38 inhibitors.
  • IL-6 stimulation of CRP production is directly inhibited by p38 inhibitors in human vascular endothelial cells, and CRP is produced by hepatocytes in response to IL-6.
  • CRP is considered a major risk factor for cardiovascular disease [ Circulation 2003.107: 363-369 ] and may be a significant independent risk factor for chronic obstructive pulmonary disease [ Circulation 2003. 107:1514-1519 ].
  • IL-6 is also upregulated in endometriosis [ Bedaiwy et al., 2002, Human Reproduction 17:426-431 ; Witz, 2000, Fertility and Sterility 73: 212-214 ].
  • Interleukin-8 (IL-8) and RANTES are chemotactic factors produced by several cell types including mononuclear cells, fibroblasts, endothelial cells, epithelial cells, neutrophils and T cells. Chemokine production is induced by pro-inflammatory stimuli such as IL-1, TNF, or lipopolysachharide (LPS), or viral infection. IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymphocytes, and basophils. In addition it induces histamine release from basophils from both normal and atopic individuals as well as lysozomal enzyme release and respiratory burst from neutrophils.
  • pro-inflammatory stimuli such as IL-1, TNF, or lipopolysachharide (LPS), or viral infection.
  • IL-8 stimulates a number of functions in vitro. It has been shown to have chemoattractant properties for neutrophils, T-lymph
  • IL-8 has also been shown to increase the surface expression of Mac-1 (CD11b/CD18) on neutrophils without de novo protein synthesis, which may contribute to increased adhesion of the neutrophils to vascular endothelial cells.
  • Mac-1 CD11b/CD18
  • Many diseases are characterized by massive neutrophil infiltration.
  • Conditions such as chronic obstructive pulmonary disease associated with an increase in IL-8 production would benefit by compounds which are suppressive of IL-8 production.
  • RANTES is produced by cells such as epithelial cells and airway smooth muscle in response to infection or cytokine stimulation. Its main chemoattraction is for T cell subtypes and blood-borne monocytes.
  • IL-1, TNF and other cytokines affect a wide variety of cells and tissues and these cytokines as well as other leukocyte derived cytokines are important as critical inflammatory mediators of a wide variety of disease states and conditions. The inhibition of these cytokines is of benefit in controlling, reducing and alleviating many of these disease states.
  • CSBP/p38 signal transduction via CSBP/p38 is required for the effector functions of several of these same pro-inflammatory proteins plus many others.
  • growth factors such as VEGF, PDGF, NGF signal through surface receptors which in turn activate cellular signaling pathways including p38 MAPK [ Ono, K. and Han, J., Cellular Signalling, 12 1-13 (2000 ); Kyriakis, JM and Avruch, J. Physiol Rev 81: 807-869 (2001 )].
  • TGF ⁇ a key molecule in the control of inflammatory response, also activates p38 as a consequence of engagement of the TGF ⁇ receptor.
  • the involvement of CSBP/p38 in multiple stress-induced signal transduction pathways provides additional rationale for the potential utility of CSBP/p38 in the treatment of diseases resulting from the excessive and destructive activation of the immune system, or chronic inflammation. This expectation is supported by the potent and diverse activities described for CSBP/p38 kinase inhibitors [ Badger, et al., J. Pharm. Exp. Thera. 279 (3): 1453-1461, (1996 ); Griswold, et al, Pharmacol. Comm. 7, 323-229 (1996 ); Jackson, et al., J. Pharmacol.
  • TGF- ⁇ transforming growth factor beta
  • p38 inhibitor SB-242235 inhibited the TGF- ⁇ -induced increases in fibronectin and thrombospondin ( Laping et al., 2002, Molec. Pharmacol. 62:58-64 ). These results show that p38 MAPK is a key signaling intermediate for the effect of the pro-fibrotic cytokine TGF- ⁇ on components of the extracellular matrix and markers of fibrosis.
  • P38 also plays a role in directing survival and apoptosis of cells in response to various stimuli. Both survival and apoptosis can be p38 regulated depending on the stimulus and the cell type [ Morin and Huot, Cancer Research. 64:1893-1898 (2004 )].
  • TGF-beta can stimulate apoptosis in murine hepatocytes through activation of gadd45b, a protein involved in cell-cycle control, in a p38 mediated process [ Yoo et al, J. Biol. Chem. 278:43001-43007, (2003 )].
  • UV-stress can activate p38 and trigger apoptosis of a damaged cell.
  • P38 has also been shown to promote survival of lymphocytes in response to stress, including neutrophils and CD8+ T cells.
  • the present invention is directed to such novel compounds which are inhibitors of p38 kinase.
  • This invention relates to the novel compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (Villa), (IX), (IXa), (A), (A1), (B), and (B1), and pharmaceutically acceptable salts, solvates or physiologically functional derivatives thereof; and pharmaceutical compositions comprising a compound of (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1), and pharmaceutically acceptable salts, solvates or physiologically functional derivatives thereof, and a pharmaceutically acceptable diluent or carrier.
  • This invention relates to a method of treating a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1).
  • This invention also relates to a method of inhibiting cytokines and the treatment of a cytokine mediated disease, in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1).
  • This invention also relates to a method of inhibiting the production of IL-1 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1).
  • This invention also relates to a method of inhibiting the production of IL-6 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1).
  • This invention also relates to a method of inhibiting the production of IL-8 in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1).
  • This invention also relates to a method of inhibiting the production of TNF in a mammal in need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1).
  • the present invention is directed to novel compounds of (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1) and a pharmaceutically acceptable salt solvate or physiologically functional derivative thereof.
  • the difference between compounds of Formula (I) and (la) lies in the unsaturation of the ring system.
  • compound of Formula (I) and (Ia) and compounds of Formula (II) and (IIa), (III) and (IIIa), (IV) and (lVa), (V) and (Va), (VI) and (VIa-VIi), etc. lies in ring substitution on the aryl or heteroaryl moiety of the R 1 substituent, and the ring position of the nitrogen(s) for the pyridyl or pyrimidine moiety where applicable.
  • R 1 , R 2 , R x , X and R 3 , etc. terms are the same for both groups within the formulas themselves, for instance, in Formula (I) and (Ia), and except for the additional G5/G6/G7/G8 terms, applicable across all formulas herein.
  • everything applicable to Formula (I) is also applicable to Formula (Ia) unless otherwise indicated, and for the remaining compounds of Formula (II) and (IIa), etc. unless specified otherwise.
  • R 1 is C(Z)N(R 10' )(CR 10 R 20 ) v R b , C(Z)O(CR 10 R 20 ) v R b , N(R 10' )C(Z)(CR 10 R 20 ) v R b , N(R 10' )C(Z)N(R 10' )(CR 10 R 20 ) v R b , or N(R 10' )OC(Z)(CR 10 R 20 ) v R b .
  • R 1 is C(Z)N(R 10' )(CR 10 R 20 ) v R b , or N(R 10' )C(Z)(CR 10 R 20 ) v R b . In another embodiment of the invention, R 1 is C(Z)N(R 10' )(CR 10 R 20 ) v R b
  • R 1' is independently selected at each occurrence from halogen, C 1-4 alkyl, halo-substituted-C 1-4 alkyl, cyano, nitro, (CR 10 R 20 ) v' NR d R d' , (CR 10 R 20 ) v' C(O)R 12 , SR 5 , S(O)R 5 , S(O) 2 R 5 , or (CR 10 R 20 ) v' OR 13 .
  • R 1' is independently selected at each occurrence from halogen, C 1-4 alkyl, or halo-substituted-C 1-4 alkyl. In another embodiment, R 1' is independently selected at each occurrence from fluorine, chlorine, methyl, or CF 3 .
  • g is 0 or an integer having a value of 1, 2, 3, or 4. In one embodiment of the invention, g is 0, 1 or 2.
  • R 1' when R 1' is substituted on a phenyl ring in the ortho position, and a second R 1' moiety is also substituted on the ring, then preferably the second substitution is not in the other ortho position.
  • the phenyl ring is substituted in the 2-position and if a second substituent is present, in the 3-position with the R 1 moiety in the 5-position.
  • the R 1' moiety may be in the other ortho 2-position and the R 1 moiety in the 3-position, which will change the ring position numbering.
  • R d and R d' are each independently selected at each occurrence from hydrogen, C 1-4 alkyl, C 3-5 cycloalkyl, C 3-5 cycloalkylC 1-4 alkyl, or the R d and R d' together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 5 to 6 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR 9' , and wherein the R d and R d' moieties which are C 1-4 alkyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-4 alkyl, and the R d and R d' cyclized ring are optionally substituted, 1 to 4 times, independently at each occurrence by halogen; halosubstituted C 1-4 alkyl; hydroxy; hydroxy substituted C 1-4 alkyl; C 1-4 alkoxy; C 1-4 alkyl; halosubstituted C 1-4 alk
  • R 9' is independently selected at each occurrence from hydrogen, or C 1-4 alkyl.
  • Z is independently selected at each occurrence from oxygen or sulfur.
  • v is 0 or an integer having a value of 1 to 2.
  • v' is 0 or an integer having a value of 1 or 2.
  • R 10 and R 20 are independently selected at each occurrence from hydrogen or C 1-4 alkyl.
  • R 10' is independently selected at each occurrence from hydrogen or C 1-4 alkyl.
  • R 12 is independently selected at each occurrence from hydrogen, C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl C 1-4 alkyl, aryl, arylC 1-4 alkyl, heteroaryl, heteroarylC 1-4 alkyl, heterocyclyl, or heterocyclylC 1-4 alkyl, and wherein these moieties, excluding hydrogen, may be optionally substituted.
  • R 13 is independently selected at each occurrence from hydrogen, C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl C 1-4 alkyl, aryl, arylC 1-4 alkyl, heteroaryl, heteroarylC 1-4 alkyl, heterocyclyl, or a heterocyclylC 1-4 alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted 1 to 4 times independently at each occurrence by halogen; halosubstituted C 1-4 alkyl; C 1-4 alkyl; hydroxy; hydroxy substituted C 1-4 alkyl; C 1-4 alkoxy; halosubstituted C 1-4 alkoxy; S(O)
  • R 21', and R 31' are each independently selected at each occurrence from hydrogen or C 1-4 alkyl, or R 21' and R 31' together with the nitrogen to which they are attached cyclize to form an optionally substituted heterocyclic 5 to 7 membered ring, which ring optionally contains an additional heteroatom selected from O/N/S.
  • R b is hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic, or a heterocyclylC 1-10 alkyl moiety, which moieties, excluding hydrogen are all optionally substituted.
  • R b moieties may be optionally substituted, one or more times, preferably 1 to 4 times independently at each occurrence by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy, such as methoxy or ethoxy; halosubstituted C 1-10 alkoxy; OR 8 , such as methoxy, ethoxy or phenoxy; SR 5 , S(O)R 5 , S(O) 2 R 5 , such as methylthio, methylsulfinyl or methyl sulfonyl; C(O)R j ; C(O)OR j ; C(O)NR 4'' R 14'' ; cyano; nitro; NR 15 R 25 ; -Z'-(CR 10 R 20 )s-Z'-; C 1-10 alkyl; C 3-7 cycloalkyl or a C
  • halogen
  • the moiety -Z'-(CR 10 R 20 )s-Z' forms a cyclic ring, such as a dioxalane ring.
  • Z' is independently at each occurrence selected from oxygen or sulfur.
  • s is independently selected at each occurrence from an integer having a value of 1, 2, or 3.
  • R 5 is independently selected at each occurrence from hydrogen, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl or NR 4' R 14' , excluding the moieties SR 5 being SNR 4' R 14' , S(O) 2 R 5 being SO 2 H and S(O)R 5 being SOH.
  • R 4' and R 14' are each independently selected at each occurrence from hydrogen or C 1-4 alkyl, or R 4' and R 14' can cyclize together with the nitrogen to which they are attached to form an optionally substituted 5 to 7 membered ring which optionally contains an additional heteroatom from oxygen, sulfur or NR 9' .
  • R 4' and R 14' cyclize to form an optionally substituted ring, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine (including oxidizing the sulfur).
  • R 4'' and R 14'' are each independently selected at each occurrence from hydrogen or C 1-10 alkyl, or R 4'' and R 14'' can cyclize together with the nitrogen to which they are attached to form an optionally substituted 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, sulfur or NR 9' .
  • R 4'' and R 14'' cyclize to form an optionally substituted ring, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine (including oxidizing the sulfur).
  • R f is independently selected at each occurrence from hydrogen, C 1-10 alkyl, aryl, aryl C 1-10 alkyl, heteroaryl, heteroaryl C 1-10 alkyl, heterocyclic, or a heterocyclic C 1-10 alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted.
  • R j is independently selected at each occurrence from a C 1-10 alkyl, aryl, aryl C 1-10 alkyl, heteroaryl, heteroaryl C 1-10 alkyl, heterocyclic, or a heterocyclicC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted.
  • R b is an optionally substituted C 1-10 alkyl
  • the moiety includes but is not limited to a methyl, ethyl, n-propyl, isopropyl, t-butyl, n-butyl, isobutyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, heptyl, 2-methylpropyl; a halosubstituted alkyl, such as 2,2,2-trifluroethyl, trifluoromethyl, 2-fluoroethyl; a cyano substituted alkyl, such as cyanomethyl, cyanoethyl; an alkoxy, thio or hydroxy substituted alkyl, such as 2-methoxy-ethyl, 2-hydroxy propyl or serinol, or an ethylthioethyl.
  • R b is an optionally substituted C 1-10 alkyl the moiety is a methyl, ethyl, n-propyl, isopropyl, t-butyl, n-butyl, or 2,2-dimethylpropyl or 2-hydroxy propyl group.
  • the heteroaryl containing moiety includes but is not limited to, furyl, pyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, oxathiadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and uracil, indolyl, isoindolyl, indazolyl, indolizinyl, azaindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, quinolyl
  • R b when R b is an optionally substituted heteroaryl it is a 1,3-thiazol-2-yl or 5-methyl-1,3-thiazol-2-yl, isoquinolinyl, thiophene, e.g. a 3-thiophene, indol-5-yl, pyridinyl, e.g. a pyridin3-yl, or pyridine-4-yl, indazolyl, benzothiazolyl, 2-methyl-1,3-benzothiazol-5-yl, 1 H -imidazol-4-yl or 1 H -imidazol-4-ylethyl.
  • the heteroaryl ring is an optionally substituted thiazolyl, pyridyl, or thiophene ring.
  • R b is an optionally substituted 1,3-thiazol-2-yl.
  • the heterocyclic containing moiety includes but is not limited to tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), azepine, diazepine, aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).
  • the heterocyclic, heterocyclic alkyl group is pyrazol-3-yl, 4-morpholino, unsubstituted and substituted 2-furanyl, 2-furanylmethyl, 2-thienyl, 2-thienylmethyl, tetrahydro-2H-pyran-4yl, tetrahydro-2H-pyran-4yl methyl, tetrahydro-2-furanyl, or tetrahydro-2-furanylmethyl.
  • R b is an optionally substituted aryl or arylalkyl moiety
  • the aryl containing moiety is unsubstituted or substituted independently at each occurrence one or more times by halogen, alkyl, cyano, OR 8 , SR 5 , S(O) 2 R 5 , C(O)R j , C(O)OR j , -Z'-(CR 10 R 20 )s-Z', halosubstituted C 1-10 alkyl, or an optionally substituted aryl.
  • R b is a phenyl, or napthylene, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorphenyl, 2,4-diflurophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 2-methyl phenyl, 3-methylphenyl, 4-methylphenyl, 6-methyl phenyl, 2-methyl phenyl, 3-amino phenyl, 3,4-dimethyl phenyl, 4-methyl-3-fluorophenyl, 4-trifluorophenyl, 4-ethoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-thiomethylphenyl, 4-acetylphenyl, 4-dimethylaminophenyl, benzyl,
  • R b is a phenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-diflurophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 4-methyl-3-fluorophenyl, 4-trifluorophenyl, 2-methylphenyl, 3-methylphenyl, 4-ethoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-thiomethylphenyl, 4-acetylphenyl, 4-dimethylaminophenyl, biphenyl, 4'-fluorobiphenyl, 4-sulfonamindo-2-methylphenyl, 3-phenyloxyphenyl, benzyl, or phenethyl.
  • R b is a 4-fluoropheny
  • R b is an optionally substituted cycloalkyl or cycloalkyl alkyl moiety
  • the moiety is a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, or a cyclopentylmethyl.
  • R b is a cyclopropyl or cyclopropylmethyl group.
  • R b is C 1-10 alkyl, heteroaryl, or aryl, all optionally substituted.
  • R b is hydrogen, or an optionally substituted alkyl.
  • R b is an alkyl, such as propyl or isopropyl; heteroaryl, such as a thiazolyl; an aryl, such phenyl, or 4-F phenyl; an arylalkyl, or a cycloalkylalkyl moiety, all optionally substituted.
  • R b is alkyl, heteroaryl, or aryl, all optionally substituted.
  • R b is C 1-10 alkyl, heteroaryl, or aryl, all optionally substituted.
  • m is independently selected at each occurrence from 0 or an integer having a value of 1 or 2.
  • n, n', m, q', s, t, or v', etc. are independently chosen at each occurrence.
  • R 8 is independently selected at each occurrence from hydrogen, C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-4 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl C 1-4 alkyl, aryl, arylC 1-4 alkyl, heteroaryl, heteroarylC 1-4 alkyl, heterocyclyl, or a heterocyclylC 1-4 alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted 1 to 4 times by halogen; halosubstituted C 1-4 alkyl; C 1-4 alkyl; C 3-5 cycloalkyl; C 3-5 cycloalkyl C 1-4 alkyl; halosubstituted C 1-4 alkyl; hydroxy; hydroxy substitute
  • R 15 and R 25 are each independently selected at each occurrence from hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, aryl, or aryl-C 1-4 alkyl, heteroaryl or heteroaryl C 1-4 alkyl moiety, and wherein these moieties, excluding hydrogen may be optionally substituted; or R 15 and R 25 together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR 9 ; and wherein these moieties are optionally substituted 1 to 4 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy; halosubstituted C 1-10 alkoxy; C 1-4 alkyl; SR 5 , S(O)R 5 ,
  • R 4 and R 14 are each independently selected at each occurrence from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted C 3-7 cycloalkylC 1-4 alkyl, optionally substituted aryl or optionally substituted aryl-C 1-4 alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C 1-4 alkyl, optionally substituted heterocyclic, or optionally substituted heterocyclic C 1-4 alkyl, or R 4 and R 14 together with the nitrogen to which they are attached may form an optionally substituted heterocyclic ring of 4 to 7 members which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen.
  • R 4 and R 14 moieties excluding hydrogen, of C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl, heteroaryl C 1-4 alkyl, heterocyclic, or heterocyclic C 1-4 alkyl moieties, and the R 4 and R 14 cyclized ring, are all be optionally substituted, one or more times, preferably 1 to 4 times, independently at each occurrence, by halogen, such as fluorine, chlorine, bromine or iodine; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy, such as methoxy or ethoxy; C 1-10 alkyl, halosubstituted C 1-10 alkoxy; SR 5 ; S(O)R 5 ; S(O) 2 R 5 such as methyl thio, methylsulfinyl or methyl sulfony
  • such rings include, but are not limited to pyrrolidine, piperidine, piperazine, morpholine, and thiomorpholine (including oxidizing the sulfur).
  • R 6 is independently selected at each occurrence from hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl or a heteroarylC 1-10 alkyl moiety, and wherein these moieties, excluding hydrogen may be optionally substituted independently at each occurrence, one or more times, suitably 1 to 2 times, by halogen; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy; halosubstituted C 1-10 alkoxy; S(O)m alkyl; C(O); NR 4' R 14 '; C 1-10 alkyl; C 3-7 cycloalkyl; C 3-7 cycloalkyl C 1-10 alkyl; halosubstituted C 1-10 alkyl; an unsubstituted aryl or aryl C 1-4 alkyl, an unsubstituted
  • R 9 is independently selected at each occurrence from hydrogen, C(Z)R 6 , optionally substituted C 1-10 alkyl, optionally substituted aryl or optionally substituted aryl-C 1-4 alkyl.
  • These alkyl, aryl and arylalkyl moieties may be optionally substituted 1 or 2 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy; halosubstituted C 1-10 alkoxy; S(O)m alkyl; -C(O); NR 4' R 14' ; C 1-10 alkyl, C 3-7 cycloalkyl; C 3-7 cycloalkyl C 1-10 alkyl; halosubstituted C 1-10 alkyl; an aryl or aryl C 1-4 alkyl, and wherein these aryl containing moieties may also be substituted one or two times independently at each occurrence by halogen, hydroxy, hydroxy
  • R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic, or heterocyclylC 1-10 alkyl moiety, which moieties may be optionally substituted one ore more times, suitably 1 to 4 times, independently at each occurrence by hydrogen, halogen, nitro, C 1-10 alkyl, halo-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-10 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl-C 1-10 alkyl, (CR 10 R 20 ) n OR 6 , (CR 10 R 20 ) n SH, (CR 10 R 20 ) n S
  • the R 3 moieties are optionally substituted 1 to 4 times, independently at each occurrence by halogen, nitro, C 1-4 alkyl, halo-substituted C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, C 3-6 cycloalkyl, C 3-6 cycloalkylC 1-4 alkyl, C 5-6 cycloalkenyl, C 5-6 cycloalkenylC 1-4 alkyl, (CR 10 R 20 ) n OR 6 , (CR 10 R 20 ) n SH, (CR 10 R 20 ) n S(O) m R 7 , (CR 10 R 20 ) n NHS(O) 2 R 7 , (CR 10 R 20 ) n S(O) 2 NR 16 R 26 , (CR 10 R 20 ) n NR 16 R 26 , (CR 10 R 20 ) n CN, (CR 10 R 20 ) n C(Z)R 6 , (CR 10 R
  • the R 3 moieties are optionally substituted independently, one or more times, suitably 1 to 4 times, independently at each occurrence by the R 3 optional substituent is independently selected from halogen, C 1-10 alkyl, (CR 10 R 20 ) n OR 6 , (CR 10 R 20 ) n NR 16 R 26 , or halo-substituted C 1-10 alkyl.
  • the optional substituents are independently selected at each occurrence from halogen, C 1-10 alkyl, hydroxy, C 1-10 alkoxy, cyano, nitro, amino, or halosubstituted C 1-10 alkyl.
  • the R 3 substituents are selected independently from halogen, such as fluorine, chlorine, bromine or iodine, or C 1-10 alkyl, such as methyl.
  • the R 3 moieties are selected from an optionally substituted C 1-10 alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted C 3-7 cycloalkylalkyl, or an optionally substituted aryl.
  • the R 3 moiety is selected from an optionally substituted C 1-10 alkyl, or an optionally substituted aryl.
  • R 3 is an optionally substituted phenyl.
  • R 3 is a phenyl ring substituted one or more times by independently at each occurrence by fluorine, chlorine, hydroxy, methoxy, amino, methyl, or trifluoromethyl.
  • R 3 is a 2,6-difluorophenyl.
  • R 3 is an aryl moiety
  • it is a phenyl ring.
  • the phenyl ring is optionally substituted, independently at each occurrence, one or more times, suitably 1 to 4 times by halogen, C 1-4 alkyl, or halo-substituted-C 1-4 alkyl.
  • the phenyl ring may suitably be substituted in the 2, 4, or 6-position, or di-substituted in the 2,4- position, or 2,6-position, such as 2-fluoro, 4-fluoro, 2,4-difluoro, 2,6-difluoro, or 2-methyl-4-fluoro; or tri-substituted in the 2,4,6-position, such as 2,4,6-trifluoro.
  • R 7 is independently selected at each occurrence from C 1-6 alkyl, aryl, arylC 1-6 alkyl, heterocyclic, heterocyclylC 1-6 alkyl, heteroaryl, or heteroarylC 1-6 alkyl; and wherein each of these moieties may be optionally substituted one or two times independently at each occurrence, by halogen; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy; halosubstituted C 1-10 alkoxy; S(O)malkyl; C(O); NR 4' R 14' ; C 1-10 alkyl; C 3-7 cycloalkyl; C 3-7 cycloalkylC 1-10 alkyl; halosubstituted C 1-10 alkyl; an aryl or aryl C 1-4 alkyl moiety, and wherein these aryl containing moieties may also be substituted one to two times by halogen, hydroxy, hydroxy substituted alkyl, C
  • R 16 and R 26 are each independently selected at each occurrence from hydrogen, or C 1-4 alkyl; or the R 16 and R 26 together with the nitrogen which they are attached form an unsubstituted or substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR 9' .
  • n is 0, or an integer having a value of 1 to 10.
  • X 1 is N(R 11 ), O, S(O) m , or CR 10 R 20 .
  • X 1 is N(R 11 ), or O.
  • R h is selected from an optionally substituted C 1-10 alkyl, -CH 2 -C(O)-CH 2 -, -CH 2 -CH 2 -O-CH 2 -CH 2 -, -CH 2 -C(O)N(R 10' )CH 2 -CH 2 -, -CH 2 -N(R 10' )C(O)CH 2 -, -CH 2 -CH(OR 10' )-CH 2 -, -CH 2 -C(O)O-CH 2 -CH 2 -, or -CH 2 -CH 2 -O-C(O) CH 2 -.
  • Rq and Rq ' are independently selected at each occurrence from hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-10 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl-C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic, or a heterocyclylC 1-10 alkyl moiety, and wherein all of the moieties, excluding hydrogen, are optionally substituted, or Rq and Rq ' together with the nitrogen to which they are attached form an optionally substituted heterocyclic ring of 5 to 7 members, which ring may contain an additional heteroatom selected from oxygen, nitrogen or sulphur.
  • R 11 is independently selected at each occurrence from hydrogen, or C 1-4 alkyl.
  • R 2 is independently selected from hydrogen, optionally substituted C 1-10 alkyl, optionally substituted C 3-7 cycloalkyl, optionally substituted C 3-7 cycloalkylalkyl, optionally substituted aryl, optionally substituted arylC 1-10 alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1-10 alkyl, optionally substituted heterocyclic, optionally substituted heterocyclylC 1-10 alkyl moiety; or R 2 is the moiety (CR 10 R 20 ) q' X 1 (CR 10 R 20 ) q C(A 1 )(A 2 )(A 3 ), or (CR 10 R 20 ) q' C(A 1 )(A 2 )(A 3 ).
  • q' is 0, or an integer having a value of 1 to 6.
  • the R 2 moieties may be optionally substituted one or more times, preferably 1 to 4 times, independently at each occurrence by C 1-10 alkyl, halo-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-7 cycloalkyl, C 3 - 7 cycloalkylC 1-10 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl C 1-10 alkyl, halogen, -C(O), cyano, nitro, (CR 10 R 20 ) n OR 6 , (CR 10 R 20 ) n SH, (CR 10 R 20 ) n S(O) m R 7 , (CR 10 R 20 ) n N(R 10' )S(O) 2 R 7 , (CR 10 R 20 ) n NR e R e', (CR 10 R 20 ) n NR e R e' C 1-4 al
  • R e are R e' are each independently selected at each occurrence from hydrogen, C 1-4 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl or a heteroaryl C 1-4 alkyl moiety, which moieties may be optionally substituted; or R e and R e' together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or NR 9 ; and wherein each of these moieties, including the cyclized ring, and excluding hydrogen, may be substituted 1 to 4 times, independently at each occurrence by halogen; hydroxy; hydroxy substituted C 1-10 alkyl; C 1-10 alkoxy; halosubstituted C 1-10 alkoxy; C 1-10 alkyl; halosubstituted C 1-4 alkyl;
  • R f' is independently selected at each occurrence from hydrogen, C 1-10 alkyl, aryl, aryl C 1-10 alkyl, heteroaryl, heteroaryl C 1-10 alkyl, heterocyclic, or a heterocyclic C 1-10 alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted.
  • the heterocyclic containing moiety is suitably selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).
  • R 2 is an optionally substituted piperidinyl or piperazinyl ring.
  • R 2 when R 2 is an optionally substituted heterocyclic or heterocyclic alkyl ring the ring is substituted one or mores times independently by an optionally substituted heterocyclic, heterocyclic alkyl, aryl, arylalkyl, alkyl, (CR 10 R 20 ) n NR e R e' , or (CR 10 R 20 ) n N(R 10' )C(Z)OR 7 .
  • the second heterocyclic ring is suitably selected from an optionally substituted tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, diazepine, morpholino or thiomorpholino (including oxidized versions of the sulfur moiety).
  • the second heterocyclic ring is selected from morpholino, piperidine, or pyrrolidinyl.
  • R 2 is a 4-amino-1-piperidinyl, 1,1-dimethylethyl)oxy]-carbonyl ⁇ amino)-1-piperidinyl, 4-methyl-1-piperazinyl, 4-ethyl-1-piperazinyl, 4-propyl-1-piperazinyl, 4-butyl-1-piperazinyl, 4-(methylamino)-1-piperidinyl, 1,1-dimethylethyl-4-piperidinyl ⁇ methylcarbamate, 4-phenyl-1-piperazinyl, 1,4'-bipiperidin-1'-yl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-methyl-1,4'-bipiperidin-1'-yl, 4-(4-morpholinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-piperazinyl, or 4-methylhexahydro-1 H-1,4-diazepin-1-yl, 4-
  • R 2' is independently selected at each occurrence from hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic, or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted 1 to 4 times, independently, at each occurrence, by C 1-10 alkyl, halo-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-10 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl C 1-10 alkyl, halogen, -C(O), cyano, nitro, aryl, aryl C 1-10 alkyl, heteroary
  • R 2' when X is (CH 2 ) n N(R 2' )(R 2'' ), one of R 2' , or R 2'' is hydrogen, or methyl.
  • R 2' is an optionally substituted heterocyclic or heterocyclylC 1-10 alkyl
  • the heterocyclic containing moiety is substituted one or more time independently by C 1-10 alkyl, aryl, heterocyclic, (CR 10 R 20 ) n NR e R e' , (CR 10 R 20 ) n N(R 10' )C(Z)OR 7 , or (CR 10 R 20 ) n C(Z)OR 6 .
  • R 2' is an optionally substituted C 1-10 alkyl, cycloalkyl, heterocyclic, heterocyclyl C 1-10 alkyl, heteroarylalkyl.
  • R 2' is an optionally substituted cycloalkyl it is a cyclohexyl ring.
  • the cyclohexyl ring is optionally substituted one or more times by (CR 10 R 20 ) n NR e R e'.
  • R 2' is an optionally substituted heterocyclic, or a heterocyclylC 1-10 alkyl
  • the ring is selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, diazepine, hexahydro-1-H-azepine, morpholino or thiomorpholino (including oxidized versions of the sulfur moiety).
  • the ring is a piperidine, piperazine, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, morpholino, hexahydro-1-H-azepine ring.
  • the rings are substituted one or more times, suitably 1 to 4 times, independently by C 1-10 alkyl, aryl, arylalkyl, (CR 10 R 20 ) n NR e R e' , or (CR 10 R 20 ) n N(R 10' )C(Z)OR 7 .
  • (CH 2 ) n N(R 2' )(R 2" ) is 1-(phenylmethyl)-4-piperidinamine, 2-[4-(phenylmethyl)-1-piperazinyl]ethylamine, 2-(1-piperidinyl)ethylamine, 2-(1-methyl-2-pyrrolidinyl)ethylamine, 1-[(phenylmethyl)-3-pyrrolidinyl]amine, 3-[(1-pyrrolidinyl)propyl] amine, 3-[(hexahydro-1H-azepin-1-yl)propyl]amine, (1-methyl-4-piperidinyl)amine, 3-[(4-morpholinyl)propyl]amine, 3-[(2-oxo-1-pyrrolidinyl)propyl]-amine, 2-[(4-morpholinyl)ethyl]amine, 2-[(1-pyrrolidinyl)ethyl]-amine, or [(1
  • R 2' is an optionally substituted C 1-10 alkyl
  • the alkyl is substituted one or more times independently by (CR 10 R 20 ) n NR e R e' or (CR 10 R 20 ) n NR e R e' C 1-4 alkylNR e R e' .
  • R e and and R e' are independently an optionally substituted C 1-4 alkyl, such as methyl, ethyl, isopropyl, n-butyl, or t-butyl.
  • (CH 2 ) n N(R 2' )(R 2" ) is 3-(dimethylamino)propyl(methyl)amine, 3-(diethylamino)propylamine, propylamine, (2,2-dimethylpropyl)amine, (2-hydroxypropyl)amino, 2-(dimethylamino)ethylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(dimethylamino)propylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(diethylamino)propylamine, 2-(methylamino)ethylamine, [(1-methylethyl)amino]ethylamine, 3-(diethylamino)propylamine, 3-(dibutylamino)propylamine, 3-[(1-methylethyl)amino]propylamine, 3-(1,1-dimethyleth
  • R 2" is selected from hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic, or a heterocyclylC 1-10 alkyl moiety, and wherein the moieties, excluding hydrogen, may be optionally substituted 1 to 4 times, independently, at each occurrence by C 1-10 alkyl, halo-substituted C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-10 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenyl C 1-10 alkyl, halogen, -C(O), cyano, nitro, aryl, aryl C 1-10 alkyl, heteroaryl, heteroarylC 1-10
  • t is an integer having a value of 2 to 6.
  • q is 0 or an integer having a value of 1 to 10.
  • a 1 is an optionally substituted C 1-10 alkyl, heterocyclic, heterocyclic C 1-10 alkyl, heteroaryl, heteroaryl C 1-10 alkyl, aryl, or aryl C 1-10 alkyl.
  • a 2 is an optionally substituted C 1-10 alkyl, heterocyclic, heterocyclic C 1-10 alkyl, heteroaryl, heteroaryl C 1-10 alkyl, aryl, or aryl C 1-10 alkyl.
  • a 3 is hydrogen or is an optionally substituted C 1-10 alkyl.
  • the A 1 , A 2 , and A 3 C 1-10 alkyl moieties may optionally substituted one or more times, independently, at each occurrence preferably from 1 to 4 times, with halogen, such as chlorine, fluorine, bromine, or iodine; halo-substituted C 1-10 alkyl, such as CF 3 , or CHF 2 CF 3 ; C 2-10 alkenyl, C 2-10 alkynyl, C 3-7 cycloalkyl, C 3-7 cycloalkylC 1-10 alkyl, C 5-7 cycloalkenyl, C 5-7 cycloalkenylC 1-10 alkyl, (CR 10 R 20 ) n OR 6 , (CR 10 R 20 ) n SH, (CR 10 R 20 ) n S(O) m R 7 , (CR 10 R 20 ) n N(R 10' )S(O) 2 R 7 , (CR 10 R 20 ) n NR 4 R 14
  • X is R 2
  • R 2 is (CR 10 R 20 ) q' X 1 (CR 10 R 20 ) q C(A 1 )(A 2 )(A 3 ), or (CR 10 R 20 ) q' C(A 1 )(A 2 )(A 3 ).
  • q' is 0.
  • R 2 is the moiety (CR 10 R 20 ) q' X 1 (CR 10 R 20 ) q C(A 1 )(A 2 )(A 3 ), q' is 0, X 1 is nitrogen, q is 0 or 1, A 1 is an optionally substituted heterocyclic or heterocyclic alkyl, and A 2 is an optionally substituted aryl. More specifically, R 2 is 2-phenyl-2-(1-pyrrolidinyl)ethyl]amino, or 1-phenyl-2-(1-pyrrolidinyl)ethyl]amino.
  • one or more of the A 1 , A 2 and A 3 moieties are substituted with (CR 10 R 20 ) n OR 6 .
  • the R 6 substituent in (CR 10 R 20 ) n OR 6 is hydrogen.
  • X is R 2 and R 2 is (CR 10 R 20 ) q' C(A 1 )(A 2 )(A 3 ), such as CH(CH 2 OH) 2 , or C(CH 3 )(CH 2 OH) 2 ; or wherein R 2 is (CR 10 R 20 ) q' X 1 (CR 10 R 20 ) q C(A 1 )(A 2 )(A 3 ) and q' is 0, and the moiety is X 1 (CR 10 R 20 ) q CH(CH 2 OH) 2 , or X 1 (CR 10 R 20 ) q C(CH 3 )(CH 2 OH) 2 ; in another embodiment X 1 is oxygen or nitrogen.
  • X is R 2 , OR 2' , (CH 2 ) n NR 4 R 14 , or (CH 2 ) n N(R 2' )(R 2" ).
  • X is S(O) m R 2' , (CH 2 ) n NR 4 R 14 , or (CH 2 ) n N(R 2' )(R 2" ).
  • X is (CH 2 ) n NR 4 R 14 , or (CH 2 ) n N(R 2' )(R 2" ).
  • X is (CH 2 ) n NR 4 R 14 .
  • X is (CH 2 ) n N(R 2' )(R 2" ).
  • X is R 2 , OR 2' , (CH 2 ) n NR 4 R 14 , or (CH 2 ) n N(R 2' )(R 2" ).
  • R 4 and R 14 are C 1-10 alkyl, aryl, aryl-C 1-4 alkyl, heterocyclic, heterocyclic C 1-4 alkyl, heteroaryl or heteroaryl C 1-4 alkyl.
  • the C 1-4 alkyl may be substituted one or more times, independently at each occurrence with NR 4' R 14' ; halogen, hydroxy, alkoxy, C(O)NR 4' R 14' ; or NR 4' C(O)C 1-10 alkyl.
  • the C 1-4 alkyl is substituted with NR 4' R 14' .
  • R 4 and R 14 may be hydrogen when R 4 and R 14 are not cyclized. In another embodiment neither R 4 and R 14 is hydrogen.
  • one of R 4 and R 14 are hydrogen, and the other is an optionally substituted heteroaryl C 1-4 alkyl.
  • the optionally substituted heteroaryl alkyl is an imidazolyl alkyl, such as a 1 H- imidazol-2-yl-methyl group.
  • the heteroaryl ring is selected from an optionally substituted thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl.
  • the heteroaryl C 1-4 alkyl is selected from an optionally substituted pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl.
  • the optionally substituted heterocyclic ring is selected from an optionally substituted tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholino.
  • the heterocyclic C 1-4 alkyl moiety is selected from optionally substituted pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholino.
  • X is (CH 2 ) n NR 4 R 14 and R 4 and R 14 together with the nitrogen cyclize to form an optionally substituted ring, such as described above, such rings include, but are not limited to pyrrolidine, piperidine, piperazine, diazepine, and morpholine.
  • the R 4 and R 14 substituents cyclize to form a heterocyclic 5 or 6 membered ring, which ring is optionally substituted as defined herein.
  • the optional substituents are suitably selected from an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, optionally substituted heterocyclic, (CR 10 R 20 ) n N(R 10' )C(Z)OR 7 , NR 4' R 14' , or a C 1-10 alkyl substituted one or more times by an optionally substituted aryl.
  • substituents more specifically include phenyl, pyrrolidinyl, morpholino, piperazinyl, 4-methyl-1-piperazinyl, piperidinyl, 2-oxo-2,3-dihydro-1 H -benzimidazol-1-yl, 5-chloro-2-oxo-2,3-dihydro-1 H -benzimidazol-1-yl, diphenylmethyl, methyl, ethyl, propyl, butyl, amino, methylamino, and dimethylamino.
  • the X substituent is a 1,4'-bipiperin-1-yl ring which may be optionally substituted such as in 4-methyl-1,4'-bipiperin-1-yl; 4-piperidinylamino, 4-amino-1-piperidinyl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-methyl-1-piperazinyl, (4-morpholinyl)-1-piperidinyl, (4-methyl-1-piperazinyl)-1-piperidinyl, 4-ethyl-1-piperazinyl, (2-oxo-2,3-dihydro-1 H -benzimidazol-1-yl)-1-piperidinyl, 5-chloro-(2-oxo-2,3-dihydro-1 H- benzimidazol-1-yl)-1-piperidinyl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-pipe
  • the X substituent is an optionally substituted 1,4'-bipiperin-1'yl ring, a 4-amino-1-piperidinyl, or a 2,2,6,6-tetramethyl-4-piperidinyl)amino.
  • R 2' is an optionally substituted C 1-10 alkyl moiety
  • the alkyl is substituted by (CR 10 R 20 ) n NR e R e'
  • R e and R e' are hydrogen, or an optionally substituted C 1-10 alkyl.
  • the X moiety is 3-(diethylamino)propylamino, 3-(dimethylamino)propyl(methyl)amino, 3-(dimethylamino)propyl(methyl)amino, 2-(dimethylamino)ethylamino, 1-(methylethyl)amino-propylamino, (1,1-dimethylethyl)aminopropylamino, (1-methylethyl)aminoethylamino, 2-(methylamino)ethylamino, 2-aminoethyl(methyl)amino, or a 2-(dimethylamino)ethyl(methyl)amino.
  • heteroaryl moiety is suitably an optionally substituted imidazole.
  • At least one of R 4 and R 14 may be hydrogen when R 4 and R 14 are not cyclized.
  • R 3 is a 2,6-difluoro phenyl
  • R 1' is independently selected at each occurrence from hydrogen, fluorine, or methyl
  • g is 1 or 2
  • R 1 is selected from C(Z)N(R 10' ) (CR 10 R 20 ) v R b , or C(Z)O(CR 10 R 20 ) v R b , or N(R 10' )C(Z)(CR 10 R 20 ) v R b .
  • R 1 is selected from C(Z)N(R 10' )(CR 10 R 20 ) v R b .
  • the R b moiety is selected from thiazolyl, C 1-10 alkyl or an optionally substituted aryl. In another embodiment the R b moiety is propyl or 4-fluorophenyl. In another embodiment, the R b moiety is thiazolyl.
  • X is suitably selected from (1 H -imidazol-2-ylmethyl)amino or 4-methyl-1,4'-bipiperidin-1'-yl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-amino-1-piperidinyl, 3-(diethylamino)propylamino, 3-(dimethylamino)propyl(methyl)amino , 3-(dimethylamino)propyl(methyl)amino, 2-(dimethylamino)ethylamino, 1-methylethyl)amino-propylamino, (1,1-dimethylethyl)aminopropylamino, (1-methylethyl)aminoethylamino, 2-(methylamino)ethylamino, 2-aminoethyl(methyl)amino, or 2-(dimethylamino)ethyl(methyl)amino
  • R 3 is a 2,6-difluoro phenyl, R 1' is independently selected at each occurrence from hydrogen, fluorine, or methyl; g is 1 or 2; and R 1 is selected from C(Z)N(R 10' )(CR 10 R 20 ) v R b , R b moiety is C 1-10 alkyl or an optionally substituted aryl, preferably propyl or 4-fluorophenyl, or optionally substituted heteroaryl, preferably thiazolyl; X is (CH 2 ) n N(R 2' )(R 2" ), and n is 0.
  • X is (CH 2 ) n N(R 2' )(R 2" ), R 2" is hydrogen, n is 0, and R 2' is an alkyl substituted by (CR 10 R 20 ) n NR e R e' .
  • R e and R e' are independently selected from an optionally substituted C 1-4 alkyl, such as methyl, ethyl, isopropyl, n-butyl, or t-butyl, preferably ethyl.
  • Another embodiment of the invention is the genus of compounds of formula (Ic), a subgenus of compounds of Formula (I) and (Ia) wherein R 1 is C(Z)N(R 10' )(CR 10 R 20 ) v R b , and R b is an optionally substituted heteroaryl, an optionally substituted heteroaryl C 1-10 alkyl, optionally substituted heterocyclic and optionally substituted heterocyclic C 1-10 alkyl.
  • R 1 is C(Z)N(R 10' )(CR 10 R 20 ) v R b
  • R b is an optionally substituted heteroaryl, an optionally substituted heteroaryl C 1-10 alkyl, optionally substituted heterocyclic and optionally substituted heterocyclic C 1-10 alkyl.
  • the remaining groups are the same as enumerated above for Formula (I) and (Ia).
  • R 1 is C(Z)N(R 10' )(CR 10 R 20 ) v R b
  • R b is an optionally substituted heteroaryl, or an optionally substituted heteroaryl C 1-10 alkyl.
  • heteroaryl, heteroarylalkyl, heterocyclic and heterocyclicalkyl moieties are as defined above for Formula (I) and (Ia).
  • a preferred heteroaryl ring is an optionally substituted thiazolyl ring, pyridyl, or thiophene ring.
  • R 1' is independently selected hydrogen, halogen, C 1-4 alkyl, or halo-substituted-C 1-4 alkyl. In another embodiment, R 1' is independently selected from hydrogen, fluorine, chlorine, methyl, or CF 3 . In one embodiment when R 1' is substituted on the phenyl ring in the ortho position, and a second R 1' moiety is also substituted on the ring, then preferably the second substitution is not in the other ortho position.
  • g is 1 or 2.
  • R 3 is an aryl moiety
  • it is a phenyl ring
  • the phenyl ring is optionally substituted, independently at each occurrence, one or more times, suitably 1 to 4 times by halogen, C 1-4 alkyl, or halo-substituted-C 1-4 alkyl.
  • the phenyl ring may suitably be substituted in the 2, 4, or 6-position, or di-substituted in the 2,4- position, such as 2-fluoro, 4-fluoro, 2,4-difluoro, 2,6-difluoro, 6-difluoro, or 2-methyl-4-fluoro; or tri-substituted in the 2,4,6-position, such as 2,4,6-trifluoro.
  • R 3 is a 2,6-difluoro phenyl.
  • R 3 is a 2,6-difluoro phenyl, R 1' is independently selected at each occurrence from hydrogen, fluorine, or methyl; g is 1 or 2.
  • the compounds of Formula(s) (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1) may also include for the X term the B-Non-Ar-cyc moiety as disclosed in US 6,809,199 whose disclosure is incorporated by reference herein.
  • Non-Ar-Cyc is suitably selected from;
  • R 7' , R 77 and R 77" are each independentlyselcted from hydrogen, C 1 - 6 alkyl-group, C 2-6 alkenyl-group, C 4-6 cycloalkyl-C 0-6 alkyl-group, N(C 0-4 alkyl)(C 0-4 alkyl)-C1-4 alkyl-N(C 0-4 alkyl)-group, -N(C 0-4 alkyl)(C 0-4 alkyl) group, C 1-3 alkyl-CO—C 0-4 alkyl-group, C 0-6 alkyl-O ⁇ C(O)—C 0-4 alkyl-group, C 0-6 alkyl-C(O)-O—C 0-4 alkyl-group, N(C 0-4 alkyl)(C 0-4 alkyl)-(C 0-4 alkyl)C(O)(C 0-4 alkyl)-group, phenyl-C 0-4 alkyl-
  • B is -C 1-6 alkyl-, -C 0-3 alkyl-O-C 0-3 alkyl-, -C 0-3 alkyl-NH-C 0-3 alkyl-, -C 0-3 alkyl-NH-C 3-7 cycloalkyl-, -C 0-3 alkyl-N(C 0-3 alkyl)-C(O)-C 0-3 alkyl-, -C 0-3 alkyl-NH ⁇ SO 2 -C 0-3 alkyl-, -C 0-3 alkyl-, -C 0-3 alkyl-S-C 0-3 alkyl-, -C 0-3 alkyl-SO 2 -C 0-3 alkyl-, -C 0-3 alkyl-PH-C 0-3 alkyl-, C 0-3 alkyl -C(O)-C 0-3 alkyl, or a direct bond.
  • E 2 is CH 2 , CHR 77 , C(OH)R 77 NH, NR 77 , O, S, -S(O)-, or -S(O) 2 -.
  • R 66 is independently selected from at each occurrence from halogen, C 0-4 alkyl, -C(O)-O (C 0-4 alkyl), or -C(O)-N(C 0-4 alkyl)-(C 0-4 alkyl).
  • the compounds of Formula(s) (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1) may also include for the X term, the X moieties as disclosed in WO 2004/073628, published September 2004, Boehm et al. , whose disclosure is incorporated by reference herein.
  • Another aspect of the invention are compounds of the formula:
  • Another aspect of the invention are compounds of Formula (A) and (A1): wherein
  • the present invention is directed to novel compounds of Formula (A) and Formula (A1), or a pharmaceutically acceptable derivative thereof.
  • the difference between compounds of Formula (A) and Formula (A1), and that of Formula (I) and (Ia) lies in the linker Y.
  • the respective R 1 , R 2 , and R 3 , etc. terms are the same for both groups.
  • everything applicable to Formula (I) is also applicable to Formula (A) unless otherwise indicated.
  • linker Y may be present in a similar manner in the same position for all of the remaining formulas, Formula's (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), etc., herein.
  • the respective R 1 , R 2 , and R 3 , etc. terms will be the same for all the groups.
  • the X term may also be the B-Non-Ar-cyc moiety as disclosed above.
  • the X term may also be the X moiety as disclosed in WO 2004/073628, published September 2004, Boehm et al. , whose disclosure is incorporated by reference herein.
  • the template containing the G 1 and G 2 moieties will have a numbering system that allows for different (R 1 and R 1' ) substituents on the phenyl, the pyridyl and pyrimidine ring at the C 4 position of the pharmacophore; the X term at the C 2 position and the R 3 substituent in the N 8 position.
  • R 1 , R 2 , R x , X and R 3 , etc. terms are the same for both groups within the formulas themselves, for instance, in Formula (VIII) and (VIIIa). For purposes herein, everything applicable to Formula (VIII) is also applicable to Formula (VIIIa) unless otherwise indicated.
  • the present invention covers all combinations of particular and preferred groups described hereinabove. It is also to be understood that the present invention encompasses compounds of formula (I) in which a particular group or parameter, for example R 5 , R 6 , R 9 , R 10 , R 11 , R 12 , R 13 , p, n, or q, etc. may occur more than once. In such compounds it will be appreciated that each group or parameter is independently selected from the values listed. When any variable occurs more than one time in a Formula (as described herein), its definition on each occurrence is independent of its definition at every other occurrence.
  • Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically derivatives.
  • salts and solvates of compounds of the invention which are suitable for use in medicine are those wherein the counterion or associated solvent is pharmaceutically acceptable.
  • salts and solvates having non-pharmaceutically acceptable counterions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds of the invention and their pharmaceutically acceptable salts and solvates.
  • pharmaceutically acceptable derivative means any pharmaceutically acceptable salt, solvate or prodrug e.g. ester, of a compound of the invention, which upon administration to the recipient is capable of providing (directly or indirectly) a compound of the invention, or an active metabolite or residue thereof.
  • pharmaceutically acceptable derivatives are salts, solvates, esters, carbamates and phosphate esters.
  • pharmaceutically acceptable derivatives are salts, solvates and esters.
  • pharmaceutically acceptable derivatives are salts and esters, in particular salts.
  • the compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt.
  • suitable salts see Berge et al., J. Pharm. Sci., 1977, 66, 1-19 .
  • a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate.
  • the salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.
  • Salts of the compounds of the present invention may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I). Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention.
  • Suitable addition salts are formed from acids which form non-toxic salts and examples are acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, ethanesulphonate, formate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydrogen phosphate, hydroiodide, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulf
  • Pharmaceutically acceptable base salts include ammonium salts such as a trimethylammonium salt, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.
  • ammonium salts such as a trimethylammonium salt
  • alkali metal salts such as those of sodium and potassium
  • alkaline earth metal salts such as those of calcium and magnesium
  • salts with organic bases including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.
  • solvates refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent.
  • solvents for the purpose of the invention may not interfere with the biological activity of the solute.
  • suitable solvents include water, methanol, ethanol and acetic acid.
  • the solvent used is a pharmaceutically acceptable solvent.
  • suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid.
  • the solvent used is water.
  • a complex with water is known as a "hydrate”. Solvates of the compound of the invention are within the scope of the invention.
  • prodrug means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects.
  • Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series ; Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 ; and in D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19(2) 115-130 , each of which are incorporated herein by reference.
  • Prodrugs are any covalently bonded carriers that release a compound of formula (I) in vivo when such prodrug is administered to a patient.
  • Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound.
  • Prodrugs include, for example, compounds of this invention wherein hydroxy or amine groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy or amine groups.
  • representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol and amine functional groups of the compounds of formula (I).
  • esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and /or be hydrolysable under in vivo conditions in the human body. Suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.
  • halogen such as fluorine, chlorine, bromine or iodine
  • hydroxy such as fluorine, chlorine, bromine or iodine
  • C 1-10 alkoxy such as methoxy or ethoxy
  • halosubstituted C 1-10 alkoxy S(O)m alkyl, such as methyl thio, methylsulfinyl or methyl sulfonyl; a ketone (-C(O)), or an aldehyde (-C(O)R 6' ), such as C(O)C 1-10 alkyl or C(O)aryl
  • R 6' is hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, heterocyclyl, heterocyclyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl or heteroarylC 1-10 alkyl, (and wherein the R 6' moieties,
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include salts formed with both organic and inorganic acids or bases.
  • Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulphamic, sulphanilic, succinic, oxalic, fumaric, maleic, malic, glutamic, aspartic, oxaloacetic, alkyl sulphonic acid derivatives, such as methanesulphonic, or ethanesulphonic, arylsulphonic acid derivatives , such as p-toluenesulphonic, m-toluenesulphonic, benzenesulphonic, camphor sulphonic, 4-chlorobenzenesulphonic, 4-bromobenzenesulphonic, 4-phenylbenzene
  • Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexyl amine and N-methyl-D-glucamine.
  • pharmaceutically acceptable salts of compounds of Formula (I) may also be formed with a pharmaceutically acceptable cation, for instance, if a substituent group comprises a carboxy moiety.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations.
  • C 1-10 alkyl or “alkyl” or “alkyl 1-10” is used herein to mean both straight and branched hydrocarbon chain containing the specified number of carbon atoms, e.g. C 1-10 alkyl means a straight of branched alkyl chain of at least 1, and at most 10, carbon atoms, unless the chain length is otherwise limited.
  • alkyl as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, isobutyl, isopropyl, sec-butyl, tert-butyl or t-butyl and hexyl and the like.
  • alkenyl refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and containing at least one double bond.
  • C 2-6 alkenyl means a straight or branched alkenyl containing at least 2, and at most 6, carbon atoms and containing at least one double bond.
  • alkenyl as used herein include, but are not limited to ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, 3-methylbut-2-enyl, 3-hexenyl, 1,1-dimethylbut-2-enyl and the like.
  • alkoxy refers to straight or branched chain alkoxy groups containing the specified number of carbon atoms.
  • C 1-6 alkoxy means a straight or branched alkoxy containing at least 1, and at most 6, carbon atoms.
  • alkoxy as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy and hexyloxy.
  • cycloalkyl refers to cyclic radicals, such as a non-aromatic hydrocarbon ring containing a specified number of carbon atoms.
  • C 3-7 cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms.
  • Representative examples of "cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl and the like.
  • cycloalkenyl is used herein to mean cyclic radicals, such as a non-aromatic hydrocarbon ring containing a specified number of carbon atoms preferably of 5 to 7 carbons, which have at least one bond including but not limited to cyclopentenyl, cyclohexenyl, and the like.
  • alkenyl is used herein at all occurrences to mean straight or branched chain radical of 2-10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.
  • aryl is used herein to mean phenyl, naphthyl, and indene.
  • heteroaryl ring means a monocyclic five- to seven- membered unsaturated hydrocarbon ring containing at least one heteroatom selected from oxygen, nitrogen and sulfur.
  • heteroaryl rings include, but are not limited to, furyl, pyranyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, oxathiadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and uracil.
  • heteroaryl ring refers to fused aromatic rings comprising at least one heteroatom selected from oxygen, nitrogen and sulfur.
  • Each of the fused rings may contain five or six ring atoms.
  • fused aromatic rings include, but are not limited to, indolyl, isoindolyl, indazolyl, indolizinyl, azaindolyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, benzothiophenyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, cinnolinyl, purinyl, and phthalazinyl.
  • heterocyclic rings is used herein to mean a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom selected from nitrogen, oxygen, sulphur or oxidized sulphur moieties, such as S(O)m, and m is 0 or an integer having a value of 1 or 2.
  • heterocyclic rings shall also refer to fused rings, saturated or partially unsaturated, and wherein one of the rings may be aromatic, or heteroaromatic.
  • Each of the fused rings may have from four to seven ring atoms.
  • heterocyclyl groups include, but are not limited to, the saturated or partially saturated versions of the heteroaryl moieties as defined above, such as tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, tetrahydrothiophene (including oxidized versions of the sulfur moiety), azepine, diazepine, aziridinyl, pyrrolinyl, pyrrolidinyl, 2-oxo-1-pyrrolidinyl, 3-oxo-1-pyrrolidinyl, 1,3-benzdioxol-5-yl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, piperazinyl, morpholino and thiomorpholino (including oxidized versions of the sulfur moiety).
  • arylalkyl or “heteroarylalkyl” or “heterocyclicalkyl” is used herein to mean a C 1-4 alkyl (as defined above) attached to an aryl, heteroaryl or heterocyclic moiety (as also defined above) unless otherwise indicated.
  • sulfinyl is used herein to mean the oxide S(O) of the corresponding sulfide, the term “thio” refers to the sulfide, and the term “sulfonyl” refers to the fully oxidized S (O) 2 moiety.
  • aroyl is used herein to mean C(O)Ar, wherein Ar is as phenyl, naphthyl, or aryl alkyl derivative such as defined above, such group include but are not limited to benzyl and phenethyl.
  • alkanoyl is used herein to mean C(O)C 1-10 alkyl wherein the alkyl is as defined above.
  • the term "optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.
  • substituted refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.
  • the present invention covers all combinations of particular and preferred groups described hereinabove. It is also to be understood that the present invention encompasses compounds of formula (I) in which a particular group or parameter, for example R 5 , R 6 , R 9 , R 10 , R 11 , R 12 , R 13 , n, m, or t, etc. may occur more than once. In such compounds it will be appreciated that each group or parameter is independently selected from the values listed. When any variable occurs more than one time in a Formula (as described herein), its definition on each occurrence is independent of its definition at every other occurrence.
  • the compounds of the Formulas herein may have one or more asymmetric carbon atom and may occur as racemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.
  • Cis (E) and trans (Z) isomerism may also occur.
  • the present invention includes the individual stereoisomers of the compounds of the invention and where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.
  • Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C.
  • a stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically active acid or base, as appropriate.
  • Exemplified compounds of the compounds of this invention include the racemates, or optically active forms of the compounds of the working examples herein, and pharmaceutically acceptable salts thereof.
  • the compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.
  • the compounds of Formula (I) and (Ia), (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI), (VIa-VIi), (VIII), (VIIIa), (IX), (IXa), (A), (A1), (B), and (B1), may be obtained by applying the synthetic procedures described herein.
  • the synthesis provided for is applicable to producing compounds of the Formulas herein having a variety of different R 1, R 2 , X, and R 3 groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed. While a particular formula with particular substituent groups is shown herein, the synthesis is applicable to all formulas and all substituent groups herein.
  • NR 10 C(O)OR 6 from NHR 10 with an alkyl or aryl chloroformate: NR 10 C(O)NR 4 H from NHR 10 by treatment with an isocyanate, e.g.
  • Precursors of the groups R 1 , R 2 and R 3 can be other R 1 , R 2 and R 3 , etc. groups that may be interconverted by applying standard techniques for functional group interconversion.
  • a moiety is a halo substituted C 1-10 alkyl
  • a suitable azide salt e.g., sodium EDTA
  • X' is halo (e.g., chloro) to yield the corresponding C 1 - 10 alkylNHS(0) 2 R 7 compound.
  • the moiety is a halo-substituted C 1-10 -alkyl it can be reacted with an amine R 4 R 14 NH to yield the corresponding C 1-10 -alkylNR 4 R 14 compound, or can be reacted with an alkali metal salt of R 7 SH to yield the corresponding C 1-10 alkylSR 7 compound.
  • hydroxyl protecting groups include ether forming groups such as benzyl, and aryl groups such as tert-butoxycarbonyl (Boc), silyl ethers, such as t-butyldimethyl or t-butyldiphenyl, and alkyl ethers, such as methyl connected by an alkyl chain of variable link, (CR 10 R 20 ) n .
  • Amino protecting groups may include benzyl, aryl such as acetyl and trialkylsilyl groups.
  • Carboxylic acid groups are typically protected by conversion to an ester that can easily be hydrolyzed, for example, trichloethyl, tert -butyl, benzyl and the like.
  • Preparation of compounds with Formula (Ia) can be achieved through compound 2, which in turn may be constructed from aldehyde 1 as shown in Scheme 1.
  • Leaving groups LG, described as Leaving group 1 (LG1) & LG2) in Scheme 1, and elsewhere can be independently selected from -Cl, -Br, -I, or -OTf and these groups can be installed through the transformation of another functional group (e.g. -OH) by following the methods well known in the art (e.g., treatment of the -OH compound with POCl 3 ).
  • Method A is for conversion of 1 to 2.
  • Treatment of 1 with an amine R 3 NH 2 in the presence of an olefin forming agent, such as bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)-phosphonate or an acylating agent, such as acetic acid anhydride, meldrums acid or acetyl chloride affords compound 2.
  • an olefin forming agent such as bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)-phosphonate
  • an acylating agent such as acetic acid anhydride, meldrums acid or acetyl chloride affords compound 2.
  • olefin forming reagent bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate is used
  • alternative cyclization reagents include, but are not limited to bis(2,2,2-trifluoroethyl)-(ethoxycarbonylmethyl)phosphonate, bis(2,2,2-trifluoroethyl)-(isopropoxycarbonyl-methyl)phosphonate, (diethoxy-phosphoryl)-acetic acid methyl ester, (diisopropoxy-phosphoryl)-acetic acid methyl ester, (diphenyloxy-phosphoryl)-acetic acid methyl ester, (diethoxy-phosphoryl)-acetic acid ethyl ester, (diisopropoxy-phosphoryl)-acetic acid ethyl ester, or (diphenyloxy-phosphoryl)-acetic acid ethyl ester.
  • reaction solvents can be various organic solvents, such as chloroform, methylene chloride, acetonitrile, toluene, DMF, or n-methylpyrrolidine, DCM, THF, toluene, DMSO, or combinations thereof. While the reaction shows triethylamine as a base, suitable alternative bases can include, but are not limited to pyridine, diisopropyl ethyl amine, or pyrrolidone, or combinations thereof.
  • reaction temperature of this particular step in the reaction scheme can be varied from room temperature to > 100 °C, i.e. reflux temperature of the solvent.
  • this reaction process step may be performed under suitable microwave conditions.
  • Method B is for the installation of group -X [e.g., 2 to 3, 6 to (Ia), or 5 to 4]. This may or may not require first conversion of sulfide (-SMe) to sulfoxide (-SOMe) or sulfone (-SO 2 Me). This conversion can be achieved using meta- chloroperoxybenzoic acid (mCPBA) in high yield and purity. Suitable oxidation methods for use herein include use of one or two equivalents of meta- chloroperoxybenzoic acid (mCPBA) or Oxone ® to afford either the sulfoxides or sulfones or a mixture of both.
  • group -X e.g., 2 to 3, 6 to (Ia), or 5 to 4].
  • This conversion can be achieved using meta- chloroperoxybenzoic acid (mCPBA) in high yield and purity.
  • mCPBA meta- chloroperoxybenzoic acid
  • Oxone ® Oxone ®
  • Oxidation of the sulfides to sulfoxides or sulfones can also be effected by OsO 4 and catalytic tertiary amine N-oxide, hydrogen peroxide, hydrogen peroxide/NaWO4, and other peracids, oxygen, ozone, organic peroxides, potassium and zinc permanganate, potassium persulfate, and sodium hypochlorite.
  • the subsequent displacement of sulfone group -SO 2 Me (likewise, all displacement reactions mentioned below may be achieved using the sulfide -SMe or sulfoxide - SOMe) requires a suitable nucleophile (e.g., amine, alcohol) containing the unit-X.
  • Displacements with amines were usually done with an excess of amine in N-methylpyrrolidine ( Barvian et al., J. Med. Chem. (2000), 4606-4616 ). A wide range of primary amines underwent this reaction with excellent yields. In some cases (e.g., in O-displacement) an anion of the nucleophile was prepared with base (usually sodium hydride) in DMF (or DMSO) and then added to the sulfone. Yields for these reactions were usually lower.
  • the sulfone may be displaced by primary and secondary alkylamines without additional base catalysis, preferably in a polar aprotic solvent, such as but not limited to, N-methyl pyrrolidin-2-one (NMP), and at varying temperatures depending upon the nucleophilicity of the amine.
  • NMP N-methyl pyrrolidin-2-one
  • displacement of the sulfone with ethanolamine, in NMP occurred in 30 min. at 65° C, while a more hindered amine such as tris(hydroxymethyl)-aminomethane may require elevated temperatures and extended reaction times (80° C over a 24 hour reaction time).
  • the sulfone can also be displaced by a primary or secondary amine with an additional non-nucleophilic base (e.g. DIPEA) in aprotic solvents like DCM, CH 3 CN, NMP, and at varying temperatures depending upon the nucleophilicity of the amine.
  • DIPEA additional non-nucle
  • the sulfone may also be displaced with a substituted arylamine, or heteroarylamine at elevated temperatures, sometimes requiring formation of the aryl or heteroarylamine anion with sodium hydride, or other suitable base, in DMSO.
  • the sulfone may be readily displaced with aluminum salts of aryl or heteroaryl, amines as previously described in the patent literature ( WO 99/32121 , whose disclosure is incorporated by reference herein).
  • sulfone may be displaced with aryl or heteroaryl or alkyl thiols or alkyl or aryl or heteroaryl alcohols.
  • Analogs containing sulfones as the X substituents may be displaced with sodium alkoxide in the alcohol, or alternatively reactive alkoxide or phenoxide nucleophiles that may be generated from the alcohol or phenol with a suitable base such as sodium, NaH or sodium bistrimethylsilyl amide in a polar aprotic solvent such as DMSO, or run as a neat reaction.
  • the sulfone may be displaced with carbon nucleophiles.
  • Suitable carbon nucleophiles include, but not limited to aryl Grignard reagents, alkyl Grignard reagents or related organometallics such as organo lithium, zinc, tin, copper or boron. These reactions may, in some cases, require transition metal catalysis such as with Pd or Ni catalysts.
  • Method C is for coupling with appropriate aryl groups to convert 3 to compounds with Formula (Ia) (or 2 to 6).
  • This transformation may be achieved using, but not limited to boronic acids (e.g., C1A) under Suzuki cross-coupling conditions, employing a palladium catalyst, such as tetrakis(triphenylphosphine) palladium(0).
  • the cross-coupling may be performed using aryl or heteroaryl organozinc, (e.g., aryl/heteroaryl-ZnBr, aryl/heteroaryl-ZnCl, aryl/heteroaryl-Zn-R1), organocopper, [e.g., (aryl/heteroaryl) 2 -CuLi], organotin [e.g., aryl/heteroaryl-Sn(CH 3 ) 3 , aryl/heteroaryl -Sn(CH 2 CH 2 CH 2 CH 3 ) 3 ], (e.g., C1C), or other organometallic reagents (e.g., C1B) known in the art [see for example Solberg, J.; Undheim, K. Acta Chemica Scandinavia 1989, 62-68 ].
  • organocopper e.g., (aryl/heteroaryl) 2 -CuLi
  • Method D is for coupling of 2 (or 3 or 7) with an aryl group whose structure has a suitable precursor (e.g., acidic group -CO 2 H, ester group -CO 2 Me) to the final substituent R 1 in Formula (Ia).
  • a suitable precursor e.g., acidic group -CO 2 H, ester group -CO 2 Me
  • This transformation may be achieved using, but not limited to boronic acids (e.g., D1A) or protected acids (e.g., D1C, D1E) under Suzuki coupling conditions, (THF/H 2 0, and K 2 CO 3 ) employing a palladium catalyst, such as tetrakis(triphenylphosphine) palladium(0). If desired, these Suzuki coupling reactions may be run under microwave conditions.
  • the boronic acid (D1A or D1E) or ester can be synthesized either by the palladium catalyzed coupling of an aryl halide and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane or the transmetalation of an aryl halide with a Grignard reagent, e.g., isopropylmagnesium bromide followed by a trialkylborate (e.g., triethylborate) in a suitable solvent like THF.
  • a Grignard reagent e.g., isopropylmagnesium bromide followed by a trialkylborate (e.g., triethylborate) in a suitable solvent like THF.
  • the arylboronic acids, or their corresponding boronic acid esters are Aryl -boronic acid or an Aryl -boronic acid ester; e.g. Aryl B(OH) 2 , Aryl -B(O-C 1-4 alkyl) 2 , or wherein R 1 , R 10 , and R 20 is as defined for compounds of Formula (I) herein; and r is an integer having a value of 2 to 6.
  • the coupling conditions include the use of appropriate solvents.
  • solvents include, but are not limited to dioxane, THF, DMF, DMSO, NMP, acetone, water, or a combination or a mixture thereof.
  • the solvent is THF/H 2 0, or dioxane/H 2 0.
  • the coupling conditions also include the presence of catalytic amount of catalysts and these catalysts include, but not limited to tetrakis(triphenylphosphine)-palladium (0), PdCl2, Pd(OAc)2, (CH3CN)2PdCl2, Pd(dppf)2, or [1,1'-bis(diphenylphosphino)-ferrocene]-dichloropalladium(II).
  • catalysts include, but not limited to tetrakis(triphenylphosphine)-palladium (0), PdCl2, Pd(OAc)2, (CH3CN)2PdCl2, Pd(dppf)2, or [1,1'-bis(diphenylphosphino)-ferrocene]-dichloropalladium(II).
  • the coupling reaction may or may not require the presence of a base.
  • Suitable bases include, but are not limited to NaHCO 3 , KHCO 3 , Na 2 CO 3 , K 2 CO 3 , KOAc or combination or mixture thereof.
  • the base is K 2 CO 3 and KOAc.
  • the coupling reaction may or may not require heating.
  • the heating can be carried out with a regular oil bath or microwave irradiations and the temperature can be varied from room temperature to >100 °C, i.e. reflux temperature of the solvent.
  • the coupling reaction may or may not require a sealed reaction vessel and the internal pressure can be varied from one atmosphere to 100 atmospheres.
  • the aryl or heteroaryl boronic acid or ester intermediates containing the R 1 moiety, used in the Suzuki coupling reactions may or may not be commercially available and they can be prepared by utilizing proper methods in the litterature known to those with appropriate training. Examples of these methods include, but not limited to palladium catalyzed coupling of an aryl halide and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi-1,3,2-dioxaborolane or the transmetalation of an aryl halide with a Grignard reagent, e.g., isopropylmagnesium bromide followed by a trialkylborate (e.g., triethylborate) in a suitable solvent.
  • a Grignard reagent e.g., isopropylmagnesium bromide followed by a trialkylborate (e.g., triethylborate) in a suitable
  • solvents include, but not limited to CH2Cl2, chloroform, CH3CN, benzene, THF, hexane, ethyl ether, tert -butyl methyl ether, DMSO, DMF, toluene, n-methyl-pyrrolidine, dioxane.
  • the reaction temperature can be varied from -78°C to >100 °C, i.e. reflux temperature of the solvent.
  • this reaction process step may or may not be performed under suitable microwave irradiation conditions.
  • This reaction may or may not require a sealed reaction vessal and the internal pressure can be varied from one atmosphere to 100 atmospheres.
  • the cross-coupling may be performed using aryl or heteroaryl organozinc, organocopper, organotin (e.g., D1B), or other organometallic reagents (e,g,, D1D) known in the art [see for example Solberg, J.; Undheim, K. Acta Chemica Scandinavia 1989, 62-68 ]. Suitable de-protection is followed if a protected precursor (e.g.,D1C, D1D, D1E) is used.
  • a protected precursor e.g.,D1C, D1D, D1E
  • This coupling reaction may be performed utilizing aryl or heteroaryl organozinc (e.g., Aryl-ZnBr, R 1 -ZnCl, Aryl -Zn- Aryl), organocopper [e.g., (Aryl) 2 -CuLi], organotin (e.g., Aryl-Sn(CH 3 ) 3 , Aryl -Sn(CH 2 CH 2 CH 2 CH 3 ) 3 ], or other organometallic reagents to afford the cross-coupling product.
  • organozinc e.g., Aryl-ZnBr, R 1 -ZnCl, Aryl -Zn- Aryl
  • organocopper e.g., (Aryl) 2 -CuLi
  • organotin e.g., Aryl-Sn(CH 3 ) 3 , Aryl -Sn(CH 2 CH 2 CH 2 CH 3 ) 3
  • organometallic reagents e.g.
  • organozinc e.g., Aryl-ZnBr, R 1 -ZnCl, Aryl -Zn- Aryl
  • organocopper e.g., (Aryl) 2 -CuLi
  • organotin e.g., Aryl -Sn(CH 3 ) 3 , Aryl -Sn(CH 2 CH 2 CH 2 CH 3 ) 3
  • organometallic reagent is not commercially available, they can readily be prepared by utilizing proper methods, known in the literature.
  • Such solvents include, but are not limited to dioxane, THF, methylene chloride, chloroform, benzene, hexane, ethyl ether, tert -butyl methyl ether or a combination or a mixture thereof.
  • the coupling reaction may, or may not, require the presence of catalytic amount of a catalyst.
  • catalysts include, but are not limited to tetrakis(triphenylphosphine)palladium (0), PdCl 2 , Pd(OAc) 2 , (CH 3 CN) 2 PdCl 2 , Pd(dppf) 2 .
  • the reaction temperature can be varied from -78 °C to >100 °C, i.e. reflux temperature of the solvent.
  • this reaction process step may be performed under suitable microwave irradiation conditions, if needed.
  • This reaction may, or may not, require a sealed reaction vessel and the internal pressure can be varied from one atmosphere to 100 atmospheres.
  • Method E is for the transformation of the suitable precursor (e.g., acidic group -COOH in 4, 5, 9, 11, 15, 16, 17, or 18) to the final substituent R 1 .
  • This type of transformations can be achieved by utilizing well-established strategies in the art.
  • the transformation may be done in one step (such as coupling with amines HN(R 10' )R b under standard coupling conditions e.g. EDC/HOBT/ET 3 N in CH 3 CN; coupling with alcohol, HOR b under standard coupling conditions, e.g.
  • DCC DCC, DMAP in DCM to form esters or reduction to alcohol
  • step e.g., Curtuis rearrangement to form isocyanates followed by urea formation with amines or acid chloride formation followed by addition of an amine, HN(R 10' )R b or an alcohol, HOR b plus a non-nucleophilic base, e.g. DIPEA in an aprotic solvent like DCM.
  • This conversion may require a deprotection step to install the precursor at first (e.g., hydrolysis of-CO 2 Me with LiOH/THF/water to prepare -COOH).
  • Preparation of compounds with Formula (Ia) can also be achieved through compound 7, which in turn may be constructed from aldehyde 1 as shown in Scheme 2. Suitable methods from Methods A-E can be utilized to furnish appropriate conversions in Scheme 2.
  • Method F is for selective displacement of suitable aldehyde 1 with an amine (R 3 -NH 2 ).
  • This type of displacement may be achieved using triethylamine and the desired amine R 3 NH 2 in chloroform at room temperature for 10 minutes.
  • the reaction was very effective for a range of alkyl amines (78-95% yield).
  • elevated temperatures reflux or microwave irradiations
  • longer reaction times overnight or 24 hours
  • presence of NaH or Na
  • Use of the base could be omitted when 3 or more equivalent of desired amine were used.
  • Suitable bases include but are not limited to pyridine, diisopropyl ethylamine or pyrrolidine, which may also be used in an appropriate organic solvent, including but not limited to THF, diethyl ether, DCM, DMF, DMSO, toluene or dioxane.
  • Method G is for cyclization of 8 to 9. It may be achieved by mixing compound 8 with an olefin forming agent (e.g., Wittig reagents) or amide forming agent (e.g.,. acid, acid chloride, ester) or an agent with both potential reactivities such as bis(2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)-phosphonate, bis(2,2,2-trifluoroethyl)-(ethoxycarbonylmethyl)phosphonate, bis(2,2,2-trifluoroethyl)-(isopropoxycarbonylmethyl)phosphonate, (diethoxy-phosphoryl)-acetic acid methyl ester, (diisopropoxy-phosphoryl)-acetic acid methyl ester, (diphenyloxy-phosphoryl)-acetic acid methyl ester, (diethoxy-phosphoryl)-acetic acid ethyl ester, (diisopropoxy-phosphoryl)-acetic acid
  • Elevated temperatures (reflux or microwave irradiations), longer reaction times (over night or 24 hours) and presence of triethyl amine, diisopropyl ethyl amine, NaOAc, or NaH (or Na) may be necessary for reaction completion.
  • Reaction solvent can be DCM, THF, toluene, DMSO or DMF.
  • the protected group (-CO 2 Me in 8) may or may not be hydrolyzed. Either output may be utilized to the advantage of expanding structure-activity-relationship (SAR) studies.
  • the hydrolysis can be achieved by mixing with LiOH in THF/water.
  • a different protecting group at this position e.g., tert-butyl
  • may require a different de-protection method e.g., treatment with TFA).
  • suitable methods include, but not limited to, Li/NH 3 , H 2 (catalyst Rh-Al 2 O 3 ), NaBH 4 / CoCl 2 .6H 2 O, NaBH 3 CN / ZnCl 2 , LiHCu( n -Bu), or Et 3 SiH.
  • Preparation of compounds with Formula (I) may also be achieved through compound 2, which in turn may be constructed from aldehyde 1 as shown in Scheme 4. Suitable methods from Methods A-H can be utilized to furnish appropriate conversions in Scheme 4.
  • Preparation of compounds with Formula (I) may also be achieved through compound 2, which in turn may be constructed from aldehyde 1 as shown in Scheme 5. Suitable methods from Methods A-H can be utilized to furnish appropriate conversions in Scheme 5.
  • the compounds of Formula (II) and (IIa), (III) and (IIIa), (IV) and (IVa), (V) and (Va), (VI) and (VIa-VIi) may be obtained by applying the synthetic procedures described above in Schemes 1 to 5 except suitable reagents in Method C & D should be utilized. Examples of these reagents include, but not limited to those shown in Scheme 6. Suitable reagents in Method C & D for the preparation of compounds with Formula (VIb-VIi) require the presence of G5-8 in appropriate position.
  • the starting material 1-Scheme 7 may be obtained from the commercially available 4,6-dihydroxy-2-methylmercaptopyrimidine by known literature procedures, such as those noted in Santilli et al., J. Heterocycl. Chem. (1971), 445-53 , wherein POCl 3 and DMF are used.
  • the intermediate 2-Scheme 7 was produced by two different routes. In the first route, coupling of dichloro aldehyde 1-Scheme 7 with aryl amines in the presence ofNaH in DMSO ( Santilli et al., J. Heterocycl. Chem. (1971), 445-53 ) afforded the desired compound 2-Scheme 7 along with imine 13-Scheme 7. The imine was converted to aldehyde 2-Scheme 7 by treatment with aqueous HCl in THF. Conversion of 1-Scheme 7 to 2-Scheme 7 may also be achieved using triethylamine and the desired amine in chloroform at room temperature for 10 minutes.
  • reaction was very effective for a range of alkyl amines (78-95 % yield).
  • aryl amines elevated temperatures (reflux) and longer reaction time (24 hours) were necessary for reaction completion.
  • Use of the base could be omitted when 3 or more equivalent of amine were used.
  • Other suitable bases include but are not limited to pyridine, diisopropyl ethylamine or pyrrolidine, which may also be used in an appropriate organic solvent, including but not limited to THF, diethyl ether or dioxane.
  • the nitrile 9-Scheme 7 was prepared in three steps from the aldehyde 1-Scheme 7 ( Santilli et al., J. Heterocycl. Chem. (1971), 445-53 ). Coupling of dichloro nitrile 9-Scheme 7 with aryl amines in the presence of NaH in DMSO afforded the desired compound 10-Scheme 7.
  • Other suitable bases such as pyridine, diisopropyl ethylamine, or sodium may also be used in an appropriate organic solvent such as THF, DMF or dioxane.
  • Production and use of the nitrile 9-Scheme-I may also be found in PCT/US01/06688, filed March 2, 2001 whose disclosure is incorporated herein by reference in its entirety.
  • Other reduction agents such as lithium aluminum hydride, Raney Ni, or SnCl 2 , may be utilized in an appropriate organic solvent such as THF, diethyl ether or dioxane to perform the conversion of 10-Scheme 7 to 2-Scheme 7.
  • Aldehyde 2-Scheme 7 was coupled to arylboronic acids under Suzuki coupling conditions, using a palladium catalyst, such as tetrakis(triphenylphosphine) palladium(0), to afford good to excellent yields of 3-Scheme 7.
  • a palladium catalyst such as tetrakis(triphenylphosphine) palladium(0)
  • the bi-aryl coupling reaction of 2-Scheme 7 may be performed using aryl or heteroaryl organozinc, organocopper, organotin, or other organometallic reagents known to afford bi-aryl cross-coupling products such as 3-Scheme 7 [see for example Solberg, J.; Undheim, K. Acta Chemica Scandinavia 1989, 62-68 ].
  • Displacement of the chlorine in 2-Scheme 7 may also be achieved with nitrogen nucleophiles [for related aminations see US patent 3,631,045 and 3,910,913 ], sulphur nucleophiles, [see Tumkevicius, S. Liebigs Ann. 1995, 1703-1705 ], oxygen nucleophiles, or alkyl nucleophiles.
  • 3-Scheme 7 was then converted to pyridopyrimidinone 5-Scheme 7 by one of three procedures.
  • the first procedure used the Wittig reaction, as modified by Homer-Emmons, converting 3-Scheme 7 to 4-Scheme 7.
  • the aldehyde 3-Scheme 7 was treated with a suitable phosphorus ylide, such as triethyl phosphonoacetate or methyl diethylphosphonoacetate, to give the olefin intermediate 4-Scheme 7.
  • the reaction was performed under reflux, in a suitable base, such as sodium hydride, sodium methoxide, or sodium hydroxide, and in a suitable organic solvent such as diethyl ether, dioxane or ethanol.
  • the conversion of 3-Scheme 7 to 4-Scheme 7 may also be performed using the Peterson olefination reaction, or an aldol-based olefination reaction that utilizes acetic anhydride, malonic acid and its monoalkyl esters, or ethyl acetate.
  • the second procedure used a Homer-Emmons reaction with Still modification ( Still et al., Tetrahedron Lett. (1983), 4405-8 ; Jacobsen et al., Tetrahedron (1994), 4323-34 ) to produce a mixture of desired product 5-Scheme 7 and trans isomer 4-Scheme 7.
  • Trans isomer 4-Scheme 7 was isolated and converted to the desired product 5-Scheme 7 by heating to 220 °C in toluene in a sealed tube as described above.
  • the third procedure involved acetylation of 3-Scheme 7, followed by the intramolecular aldol condensation, promoted by an acetylating agent (such as acetic anhydride, acetyl chloride, or a ketene) and a suitable base (such as pyridine, diispropyl ethylamine, or pyrrolidine), to generate 5-Scheme 7 in a very good yield.
  • an acetylating agent such as acetic anhydride, acetyl chloride, or a ketene
  • a suitable base such as pyridine, diispropyl ethylamine, or pyrrolidine
  • R 3 is an arylalkyl, or heteroarylalkyl substituent it is not clear that the reaction will form the key intermediate of Formula (VII), as shown below (3a-Scheme 8), which may optionally be isolated, as shown in Scheme 8 below.
  • Compounds of Formula (VII) are preferably not isolated but further reacted with a base or with heat to cyclize into 5-Scheme-7. The first and second procedures should be utilized for all other R 3 moieties.
  • Oxidation of the sulfide 5-Scheme 7 to the sulfone 6-Scheme 7 was performed using meta -chloroperoxybenzoic acid (mCPBA) in high yield and purity.
  • Suitable oxidation methods for use herein include use of one or two equivalents of meta -chloroperoxybenzoic acid (mCPBA) or Oxone ® to afford either the sulfoxides or sulfones.
  • Oxidation of the sulfides to sulfoxides or sulfones can also be effected by OsO 4 and catalytic tertiary amine N-oxide, hydrogen peroxide, other peracids, oxygen, ozone, organic peroxides, potassium and zinc permanganate, potassium persulfate, and sodium hypochlorite.
  • Displacements of the sulfones 6-Scheme 7 to the final products 7-Scheme-7 were usually done with an excess of amine in N-methylpyrrolidine ( Barvian et al., J. Med. Chem. (2000), 4606-4616 ). A wide range of primary amines underwent this reaction with excellent yields. In some cases (in O-displacement or sulfonamide formation) an anion of the nucleophile was prepared with base (usually sodium hydride) in dimethylformamide and then added to the sulfone. Yields for these reactions were usually lower.
  • sulfone of analogs of Formula (I) compounds with ethanolamine, in NMP occurred in 30 min. at 65° C, while a more hindered amine such as tris(hydroxymethyl)-aminomethane may require elevated temperatures and extended reaction times (80° C over a 24 hour reaction time).
  • the sulfone can also be displaced by a primary or secondary amine with an additional non-nucleophilic base (e.g. DIPEA) in aprotic solvents like DCM, CH 3 CN, NMP, and at varying temperatures depending upon the nucleophilicity of the amine.
  • DIPEA additional non-nucleophilic base
  • the sulfone may also be displaced with a substituted arylamine, or heteroarylamine at elevated temperatures, sometimes requiring formation of the aryl or heteroarylamine anion with sodium hydride, or other suitable base, in DMSO.
  • the sulfoxide analogs of Formula (I) compounds may be readily displaced with aluminum salts of aryl or heteroaryl amines as previously described in the patent literature ( WO 99/32121 ).
  • sulfone and sulfoxide analogs of Formula (I) and (Ia) may be displaced with aryl or heteroaryl or alkyl thiols or alkyl or aryl or heteroaryl alcohols.
  • analogs of (I) containing sulfones as the X substituents may be displaced with sodium alkoxide in the alcohol, or alternatively reactive alkoxide or phenoxide nucleophiles may be generated from the alcohol or phenol with a suitable base such as sodium, NaH or sodium bistrimethylsilyl amide in a polar aprotic solvent such as DMSO, or run as a neat reaction.
  • sulfones related to Formula (I) and (Ia) may be displaced with carbon nucleophiles such as aryl or alkyl Grignard reagents or related organometallics such as organo lithium, zinc, tin or boron.
  • transition metal catalysis such as with Pd or Ni catalysts.
  • Transition metal catalysis such as with Pd or Ni catalysts.
  • Displacement of related 2-pyrimidine sulfones with cyanide, malonate anions, unactivated enolates, or heterocyclic C nucleophiles such as 1-methylimidazole anion, by the generation of the anion with NaH or other suitable base in THF also has precedent (see for example, Chem Pharm Bull. 1987, 4972-4976 .).
  • analogs of Formula (I) and (Ia) compounds wherein X is an alkyl sulfone may be displaced with the anion of 1-methyl imidazole, generated by treatment of 1-methyl imidazole with n-butyl lithium in a solvent such as THF at temperatures of about -70°, to afford the C-alkylated product substituted on the imidazole C-2.
  • compounds of Formulas (I), (Ia), (II) and (IIa) wherein X is R 2 or NHS(O)mR 2 may be obtained from compounds of 6-Scheme 7 by displacement of the sulfone using the appropriate "X" functionality as defined in Formula (I) and (Ia).
  • X is S(O) m R 2 and R 2 is other than methyl
  • Suitable oxidation methods for use herein include use of an oxidant such as one or two equivalents of meta -chloroperoxybenzoic acid or Oxone ® to afford either the sulfoxides or sulfones. Oxidation of the sulfides to sulfones may also be effected by OsO 4 and catalytic tertiary amine N-oxide. Other methods for sulfide oxidation include the use of hydrogen peroxide, other peracids, oxygen, ozone, organic peroxides, potassium and zinc permanganate, potassium persulfate, and sodium hypochlorite.
  • an oxidant such as one or two equivalents of meta -chloroperoxybenzoic acid or Oxone ® to afford either the sulfoxides or sulfones. Oxidation of the sulfides to sulfones may also be effected by OsO 4 and catalytic tertiary amine N
  • 8-Scheme 7 can be also prepared by heating the trans ester 4-Scheme 7 in alcohol in the presence of the corresponding sodium alkoxide. The yield of this reaction was very high for primary alcohols, but longer reaction times were required for secondary alcohols. Sodium alkoxides may be easily prepared from corresponding alcohol and base, such as sodium or sodium hydride.
  • Cyclization of the ester 11-Scheme 7 can be done utilizing sodium methoxide in methanol to give reduced analogue 12-Scheme 7.
  • Other organic bases such as sodium, sodium ethoxide or TEA can be used in an appropriate organic solvent such as methanol, ethanol or dioxane.
  • the product 12-Scheme 7 can be also obtained by heating ester 11-Scheme 7 to 150 °C in an appropriate organic solvent, such as toluene, xylene or isopropanol.
  • Method I is for the substitution of -LG 2 with appropriate compound containing the structural unit of -Y-H. This can be achieved by heating the reaction mixtures in appropriate solvents.
  • the heating method can be selected from either a regular oil bath or microwave irradiations.
  • Solvents can be CH 2 Cl 2 , DMSO, DMF, toluene, benzene, CH 3 CN or NMP.
  • the reaction may or may not require the presence of bases.
  • An example of the base can be selected from, but not limited to triethyl amine, diisopropyl ethyl amine, NaH, n -BuLi, tert -BuLi, tert -BuOK, Li 2 CO3, Cs 2 CO 3 and pyridine.
  • This transformation may also require the presence of catalytic amount of catalysts containing transition metals (e.g., Pd, Cu, Ni, or W).
  • catalysts include, but not limited to Pd/C, Pd(PPh 3 ) 4 and PdCl 2 .
  • Suitable oxidation methods for use herein include, but not limited to mCPBA, Oxone, OsO 4 , H 2 O 2 , potassium and zinc permanganate.
  • Rg is a C 1-4 alkyl, and more preferably methyl.
  • m is 0 or an integer having a value of 1 or 2. More preferably mis 0 or 2.
  • R 3 is an optionally substituted C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, or aryl.
  • R 3 optional substituents are independently selected from halogen, alkyl, hydroxy, alkoxy, amino, or halosubstituted alkyl.
  • Another aspect of the invention are compounds of Formula (C) and (C1): wherein,
  • Rg is methyl. In another embodiment, m is 0 or 1.
  • ES electrospray
  • Heating of reaction mixtures with microwave irradiations was carried out on a Smith Creator (purchased from Personal Chemistry, Forboro/MA, now owned by Biotage), a Emrys Optimizer (purchased from Personal Chemistry) or an Explorer (provided by CEM Discover, Matthews/NC) microwave.
  • the sulfide is dissolved in CHCl 3 and mCPBA (1.5eq.) is added. The mixture is allowed to stir for 30 minutes (hereinafter “min") then quenched with NaHCO 3 . The organic portion is washed with brine and dried (MgSO 4 ).
  • the resulting mixture was degassed with Argon for 5 minutes, mixed with Pd(PPh 3 ) 4 (0.232 g, 0.20 mmol) and heated with a preheated oil bath (160°C) under vigorous stirring for 30 minutes.
  • the reaction mixture was filtered through celite, concentrated under vaccum to remove DME. It was then mixed with EtOAc (200 mL) and AcOH (2.5 mL), and shaked. The layers were separated. The organic layer was collected, further washed with brine (70 mL), dried over Na 2 SO 4 , filtered, concentrated and purified via a flash chromatography (load column with DCM, mobile phase EtOAc/Hexane) to afford the title compound as a white solid 2.15g (98 %).
  • the title compound was prepared by following the procedure in Example 1d from N-(cyclopropylmethyl)-3-(8-(2,6-difluorophenyl)-2-methyl sulfone-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl)-4-methylbenzamide and 1,1-dimethylethyl 4-amino-1-piperidinecarboxylate.
  • the mixture was stirred at about 80 °C for about 1 hour, cooled to room temperature (rt), and added with water (0.2 mL), barium hydroxide octahydrate (440.0 mg, 1.40 mmol) and 4-chloro-8-(2,6-difluorophenyl)-2-(methylthio)pyrido[2,3- d ]pyrimidin-7(8 H )-one (180.0mg, 0.47mmol).
  • the mixture was heated at about 100 °C under stirring for about 1 hour, cooled to room temperature, filtered through celite, and diluted with brine (5.0 mL). The mixture was then extracted with CH 2 Cl 2 (3x10 mL).
  • the benzoic acid (1.54 g, 0.01 mol) is dissolved in trifluoromethanesulfonic acid (10 mL) and cooled to about 0°C.
  • NIS (2.25 g. 0.01 mol) is added in several portions over a 6 h period while maintaining the reaction temperature at about 0 °C.
  • the mixture is allowed to warm to rt. overnight.
  • the reaction mixture is then poured over ice and extracted with ethyl acetate (3x).
  • the organic layers are washed (Na 2 S 2 O 5 ) and concentrated.
  • the material is carried on crude.
  • the title compound was prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzoic acid and 4-fluoroaniline by following the General Procedure for EDC couplings as disclosed in the general experimental section above. Crude reaction mixture was purified via flash chromatography (EtOAc:Hexanes, 2:1) to afford the title compound (0.125 g, 34%).
  • the title compound (0.105 g, 79%) was prepared by following the General Procedure for sulfide oxidations, as disclosed above.
  • the title compound is prepared by following the General Procedure for Sulfoxide/Sulfone/sulfone displacement as disclosed above. Concentrated reaction mixture is purified via reversed-phase HPLC to give the desired compound as a white solid (43 mg, 39%): LC-MS m / z 576 (M+H) + , 1.89 min (ret time). HPLC (254nm) indicates 90% pure.
  • the borate ester (0.683 g, 2.27 mmol), chloride (0.768 g, 2.27 mmol), K 2 CO 3 (0.941 g, 6.81 mmol) and tetrakistriphenylphosphine palladium (131 mg, 0.11 mmol) are dissolved in dioxane / water (3:1) and heated at reflux for about 4 h. The reaction mixture is then taken up in ethyl acetate and washed with water, brine and dried with Na 2 SO 4 . The concentrated mixture was purified via flash chromatography to give the desired product (0.6 g, 55%).
  • the title compound is prepared according to the General Procedure for sulfide oxidation, as disclosed above. It is concentrated to give the desired product as a yellow powder (0.3 g, 49%).
  • the title compound is prepared according to the General Procedure for Sulfoxide/Sulfone/Sulfone Displacement, as disclosed above.
  • the concentrated reaction mixture is precipitated with DMSO / water, and filtered.
  • the desired product is obtained as a white solid (m.p. 326.3-327.9) 95% pure by HPLC (55 mg, 45%): LC-MS m / z 587 (M+H) + , 1.74 min (ret time).
  • the title compound is prepared from compound N -cyclopropyl-3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzamide and 4-piperidinamine by following the General Procedure for Sulfoxide/Sulfone/Sulfone Displacement, as disclosed above. The concentrated reaction mixture is precipitated with ethyl acetate/hexanes, and filtered. The desired product is obtained as a yellow solid (75 mg, 100%) 94% pure by HPLC: LC-MS m / z 531 (M+H) + , 1.65 min (ret time).
  • N -cyclopropyl-3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzamide (0.1 g, 0.2 mmol) is dissolved in DMF (10 mL) and (1 H -imidazol-2-ylmethyl)amine dihydrochloride (0.053 g, 0.4 mmol) is added followed by triethylamine (0.167 mL, 1.2 mmol). The mixture is heated to about 60 °C for about 3 h.
  • the title compound is prepared from N -cyclopropyl-3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzamide and N -propyl-1,2-ethanediamine following the General Procedure for Sulfoxide/Sulfone Displacement, disclosed above.
  • the concentrated reaction mixture is purified via reversed-phase HPLC.
  • the desired product is obtained as a yellow solid (m.p. 120-134) >95% pure by HPLC (65 mg, 61 %): LC-MS m / z 533 (M+H) + , 1.84 min (ret time).
  • the title compound is prepared from the compound from N -cyclopropyl-3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzamide and N , N' -dimethyl-1,2-ethanediamine by following the General Procedure for Sulfoxide/Sulfone Displacement, disclosed above.
  • the concentrated reaction mixture is purified via reversed-phase HPLC.
  • the desired product is obtained as an off-white solid (m.p. 214.7-217.5 °C) >95% pure by HPLC (69 mg, 67%): LC-MS m / z 519 (M+H) + , 1.54 min (ret time).
  • the title compound is prepared from the acid from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzoic acid by following the procedures in Example 19 using 2-(4-fluorophenyl)ethanamine for the amide formation and 2,2,6,6-tetramethyl-4-piperidinamine for the displacement reaction: LC-MS m / z 669 (M+H) + , 2.03 min (ret time).
  • the title compound is prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzoic acid by following the procedures in Example 19 using (cyclopropylmethyl)amine for the amide formation and 4-piperidinamine for the displacement reaction: LC-MS m / z 545 (M+H) + , 1.63 min (ret time).
  • the title compound is prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-4-methylbenzoic acid by following the procedures in Example 19 using 2-phenylethanamine for the amide formation and 2,2,6,6-tetramethyl-4-piperidinamine for the displacement reaction: LC-MS m / z 651 (M+H) + , 1.87 min (ret time).
  • the title compound is prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzoic acid_by following the procedures in Example 19 using 2-phenylethanamine for the amide formation and (2-aminoethyl)methylamine for the displacement reaction: LC-MS m / z 569 (M+H) + , 1.69 min (ret time).
  • the title compound is prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-4-methylbenzoic acid by following the procedures in Example 19 using 2-phenylethanamine for the amide formation and (1 H -imidazol-2-ylmethyl)amine dihydrochloride for the displacement reaction: LC-MS m / z 592 (M+H) + , 1.77 min (ret time).
  • 3-Thiophenecarboxylic acid (2.0 g, 15.6 mmol) was dissolved in methylene chloride (100 mL) and 2 drops of DMF were added. The mixture was cooled to about 0 °C and oxalyl chloride (1.5 mL, 17.1 mmol) was added slowly and allowed to warm to room temperature. Gas evolution was observed during warming.
  • 3-Methyl-4-iodoaniline (5.45 g, 23.5 mmol), 4 drops of pyridine and K 2 CO 3 (2.58 g, 18.7 mmol) are dissolved in CH 2 Cl 2 (10 mL) and cooled to about 0 °C.
  • the acid chloride mixture is slowly added to the cooled aniline mixture and allowed to warm to room temperature and stirred for about 18h.
  • the resulting mixture is filtered, washed with ethyl acetate and the filtrate is concentrated to a brown oil.
  • the crude material was purified via flash chromatography (10-30% ethyl acetate in hexanes) to afford the desired product (1.56 g, 29%) as an off-white solid.
  • Example 31b The title compound was prepared from the compound from Example 31b according to the procedures in Example 1b. Flash chromatography followed by recrystallization (ethyl acetate) afforded the desired compound (0.292 g, 90%).
  • the title compound was prepared from the compound from Example 31c according to General Procedure for Sulfide Oxidation. The desired compound was obtained without need for purification (0.08 g, 63%).
  • the title compound was prepared from N - ⁇ 3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylphenyl ⁇ -3-thiophenecarboxamide and 4-piperidinamine according to General Procedure for Sulfoxide/Sulfone Displacement, described above.
  • the concentrated reaction mixture was purified via reversed-phase HPLC to give the desired compound as a light tan powder (0.041 g, 32%). HPLC indicated the material to be >95% pure (m.p. 183.8-187.9): LC-MS m / z 573 (M+H) + , 1.79 min (ret time).
  • the title compound was prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzoic acid by following the procedures in Example 19 using 2-propanamine for the amide formation and N,N,N'-trimethyl-1,3-propanediamine for the displacement reaction ( 88%).
  • the resultant mixture was bubbled with argon for 5 minutes, then added by Pd(PPh 3 ) 4 (2.4 mg, 0.0021 mmol).
  • the reaction tube was sealed and heated in "Smith Creator” (microwave, 150 °C) for about 15 minutes. The mixture was concentrated under vacuo.
  • the title compound was prepared from 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline by following the procedures in Example 18e.
  • Example 79c Using material as made above in Example 79c, a reaction vessel is charged with the amorphous free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide (11.0 mg) and acetonitrile (250 ⁇ L) at room temperature (RT). The mixture is warmed to about 50°C. To the warmed mixture is added 1eq of methanesulfonic acid solution (1N in water).
  • Example 79c a reaction vessel is charged with the free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H- imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide (10.05 g) and acetone (201 mL) at room temperature (RT). The mixture is warmed to about 50°C and the temperature maintained for about 15 minutes. To the warm mixture is added 1eq of methanesulfonic acid solution (1N in water).
  • salts of the title compound were made: hydrochloric, hydrobromic, sulfuric (sulfonate), benzoic, p-toluenesulfonic (methylbenzenesulfonate), citrate, ethane sulphonic acid (ethanesulphonate), benzenesulphonic acid (benzenesulfonate), fumaric acid (fumarate).
  • Additional salts include the camphor sulphonic acid, 1.2-dichlorobenzensulphonic acid and 1,2-napthalenesulphonic acid. Single equivalents of the acid were introduced to ensure protonation of the most basic nitrogen and reduce the likelihood of protonating the other less basic nitrogens.
  • the product was filtered, washed with THF, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed.
  • the yield was 32.9% (327.0 mg) of the title compound with a melting onset at 259°C (determined by DSC).
  • acetone (535 uL) was added to amorphous free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from Example 79c (26.6 mg), and the resulting mixture was heated to about 50°C. Hydrochloric acid was added (1.0 equivalent; 1N in water) resulting in a clear solution. Seed crystals were added, and the mixture was cooled to room temperature and stirred for several hours. The product was filtered, washed with acetone, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed. The yield was 73.2% (20.7 mg).
  • Acetonitrile 250 uL was added to amorphous free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from Example 79c (11.2 mg), and the resulting mixture was heated to about 50°C. Sulfuric acid was added (1.0 equivalent; 1N in water). The mixture was cooled to room temperature and shook for several hours.
  • THF 550 uL
  • Acetonitrile (300 uL) was added to amorphous free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from Example 79c (16.0 mg) at room temperature resulting in a mixture. Hydrobromic acid was added (1.0 equivalent; 1N in water) resulting in a clear solution. The following day, a white precipitate was observed.
  • Isopropanol (200 uL) was added to free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from (10.6 mg), and the resulting mixture was heated to 50°C. Citric acid was added (1.0 equivalent; 1N in THF). The mixture was cooled to room temperature and shook for several days.
  • the product was filtered, washed with isopropanol, and dried for several hours in a vacuum oven at 50°C with a slow nitrogen bleed.
  • the yield was 61.4% (8.7 mg) of title compound with a melting onset at 179°C (determined by DSC).
  • Isopropanol (502 uL) was added to free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from (25.1 mg), and the resulting mixture was heated to 50°C. Citric acid was added (1.0 equivalent; 1N in THF) resulting in an immediate precipitate. Seed crystals were added, and the mixture stirred for several hours. The product was filtered, washed with isopropanol, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed. The yield was 71.4% (24.0 mg).
  • acetone (501 uL) was added to free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide (25.1 mg), and the resulting mixture was heated to 50°C. Ethanesulfonic acid was added (1.0 equivalent; 1N in THF). Seed crystals were added, and the mixture stirred for several days. The product was filtered, washed with acetone, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed. The yield was 78.1 % (23.3 mg).
  • Acetone 200 uL was added to free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide (10.4 mg), and the resulting mixture was heated to 50°C. Benzenesulfonic acid was added (1.0 equivalent; 1N in water) resulting in a clear solution. The mixture was cooled to room temperature and shook overnight.
  • the product was filtered, washed with acetone, and dried for several hours in a vacuum oven at 50°C with a slow nitrogen bleed.
  • the yield was 83.2% (5.8 mg) of title compound with a melting onset at 317°C (determined by DSC).
  • acetone (494 uL) was added to free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from Example (24.7 mg) at room temperature resulting in a mixture. Benzenesulfonic acid was added (1.0 equivalent; 1N in water) resulting in a clear solution. Seed crystals were added, and the mixture stirred for several hours. The product was filtered, washed with acetone, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed. The yield was 83.2% (26.3 mg).
  • the product was filtered, washed with isopropanol, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed.
  • the yield was 61.4% (6.0 mg) of title compound with a melting onset at 251°C (determined by DSC).
  • isopropanol (488 uL) was added to free-base version of 3- ⁇ 8-(2,6-difluorophenyl)-2-[(1 H -imidazol-2-ylmethyl)amino]-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl ⁇ -4-methyl- N -1,3-thiazol-2-ylbenzamide from Example 79c (24. 4 mg), and the resulting mixture was heated to 50°C. Fumaric acid was added (1.0 equivalent; 0.2 N in ethanol) resulting in an immediate precipitate. Seed crystals were added, and the mixture stirred for several hours. The product was filtered, washed with isopropanol, and dried overnight in a vacuum oven at 50°C with a slow nitrogen bleed. The yield was 63.0% (18.5 mg).
  • Example 80a To the acid from Example 80a (32.3 mg, 0.066 mmol, 1 eq) was added HATU (28.5 mg, 0.075 mmol) in DMF (500 uL). DIPEA (34 ⁇ L, 0.2 mmol, 3 eq) was then added. The resulting mixture was then allowed to stand for about 5 minutes before adding to propylamine (6 mg, 0.1 mmol) in DMF (250 uL). The resulting mixture was shaken to ensure efficient mixing of the reagents then was left to stand overnight. The solvent was then removed in vacuo. The residue dissolved in methanol and was then placed down an aminopropyl SPE flushing the column with methanol. The residue was purified by MDAP to give the above named compound (7.4 mg): LC-MS m / z 524 (M+H) + , 2.63 min (ret time).
  • N -(cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-4-yl]-4-methylbenzamide (13.5mg, 0.027mmol), was dissolved in anhydrous methanol (2 mL) and was added to a tube containing nickel chloride hexahydrate (2 mg). The tube was placed under an atmosphere of nitrogen and cooled using a dry-ice/acetone bath to about -15°C. Sodium borohydride (2 mg) was then added (nitrogen removed during addition and then replaced) and the solution turned black.
  • the title compound was prepared from 3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-7,8-dihydropyrido[2,3- d ]pyrimidin-4-yl]-4-methylbenzoic acid by following the procedures in Example 19 using 2-propanamine for the amide formation and N,N,N '-trimethyl-1,2-ethanediamine for the displacement reaction.
EP11176338.9A 2005-03-25 2006-03-24 Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38 Active EP2447266B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66531505P 2005-03-25 2005-03-25
EP06748672A EP1868611B1 (fr) 2005-03-25 2006-03-24 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
WOPCT/US2006/010855 Previously-Filed-Application 2006-03-24
EP06748672.0 Division 2006-03-24

Publications (2)

Publication Number Publication Date
EP2447266A1 true EP2447266A1 (fr) 2012-05-02
EP2447266B1 EP2447266B1 (fr) 2013-06-12

Family

ID=37053943

Family Applications (3)

Application Number Title Priority Date Filing Date
EP11176338.9A Active EP2447266B1 (fr) 2005-03-25 2006-03-24 Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38
EP06748672A Active EP1868611B1 (fr) 2005-03-25 2006-03-24 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES
EP11176337A Withdrawn EP2436686A1 (fr) 2005-03-25 2006-03-24 Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP06748672A Active EP1868611B1 (fr) 2005-03-25 2006-03-24 8-PHENYL-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDIN-7-ONES
EP11176337A Withdrawn EP2436686A1 (fr) 2005-03-25 2006-03-24 Derivé de la pyrimidopyridine utile comme modulateur de CSBP/RK/p38

Country Status (25)

Country Link
US (3) US7678801B2 (fr)
EP (3) EP2447266B1 (fr)
JP (1) JP5037487B2 (fr)
KR (1) KR101235497B1 (fr)
CN (4) CN102746301A (fr)
AR (1) AR053346A1 (fr)
AU (1) AU2006229993B2 (fr)
BR (1) BRPI0609437A2 (fr)
CA (1) CA2602553C (fr)
EA (1) EA012875B1 (fr)
ES (2) ES2398246T3 (fr)
HK (1) HK1111422A1 (fr)
IL (1) IL185870A (fr)
MA (1) MA29341B1 (fr)
MX (1) MX2007011856A (fr)
MY (2) MY145343A (fr)
NO (1) NO20075275L (fr)
NZ (1) NZ561237A (fr)
PE (2) PE20100737A1 (fr)
SG (1) SG166771A1 (fr)
TW (1) TWI389690B (fr)
UA (1) UA95444C2 (fr)
UY (1) UY29440A1 (fr)
WO (1) WO2006104915A2 (fr)
ZA (1) ZA200707564B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CZ20031125A3 (cs) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Nové sloučeniny
PL373339A1 (en) * 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
EP1868612A4 (fr) * 2005-03-25 2010-03-24 Glaxo Group Ltd Nouveaux composes
PE20100741A1 (es) * 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
US7479558B2 (en) * 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
JP2009542818A (ja) * 2006-06-16 2009-12-03 グラクソ グループ リミテッド 新規化合物
WO2007147103A2 (fr) * 2006-06-16 2007-12-21 Glaxo Group Limited Nouveaux composés
GB0621830D0 (en) * 2006-11-02 2006-12-13 Chroma Therapeutics Ltd Inhibitors of p38 mitogen-activated protein kinase
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
WO2012158197A2 (fr) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Composés utiles en tant que modulateurs akt/pkb et leurs utilisations
BR112014004437B1 (pt) 2011-08-25 2021-12-14 St. Jude Children's Research Hospital Composto, uso de um composto, composição farmacêutica, formulação farmacêutica, processo para preparação de um composto, e intermediário
CA3128468A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Inhibiteurs de la kinase p38 reduisant l'expression du gene dux4 et des genes aval pour le traitement de la fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918408A (en) 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodic compositions specific for treating spasm of the colon
US3631045A (en) 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3910913A (en) 1969-11-04 1975-10-07 American Home Prod 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
GB2064336A (en) 1979-12-06 1981-06-17 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715A1 (fr) 1981-07-08 1983-01-12 Aktiebolaget Draco Inhalateur de poudre
GB2129691A (en) 1982-10-08 1984-05-23 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265A (en) 1982-10-08 1986-07-09 Glaxo Group Ltd Pack for medicament
GB2178965A (en) 1985-07-30 1987-02-25 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2242134A (en) 1990-03-02 1991-09-25 Glaxo Group Ltd Inhalation device
WO1993013055A1 (fr) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Derives d'amidino et leur utilisation comme inhibiteurs de synthase d'oxyde nitrique
US5468751A (en) 1990-08-10 1995-11-21 Ciba-Geigy Corporation Aminopyrimidine derivatives as microbicides, insecticides and acaricides
US5474996A (en) 1991-05-23 1995-12-12 Roussel Uclaf Pyrimidine derivatives
WO1995034534A1 (fr) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Inhibiteurs d'enzymes
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1997032583A1 (fr) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Utilisations de composes csaidtm en tant qu'inhibiteurs de l'angiogenese
WO1997035856A1 (fr) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement des lesions du systeme nerveux central
US5772085A (en) 1995-03-10 1998-06-30 Minnesota Mining And Manufacturing Free flow aerosol valves
WO1998030537A1 (fr) 1997-01-13 1998-07-16 Glaxo Group Limited Inhibiteurs de monoxyde d'azote synthetase
WO1998054159A1 (fr) 1997-05-30 1998-12-03 Schering Aktiengesellschaft Acylanilides non steroidiques heterocycliquement substitues a effet mixte gestagene et androgene
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
WO1999032121A1 (fr) 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
WO1999041253A1 (fr) 1998-02-17 1999-08-19 Tularik Inc. Antiviraux derives de pyrimidine
WO1999047505A1 (fr) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de pde iii/iv a base de phtalazinones
US5998428A (en) 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
WO1999062875A1 (fr) 1998-05-30 1999-12-09 Glaxo Group Limited Inhibiteurs de synthase d'oxyde nitrique
WO2000051599A1 (fr) 1999-03-01 2000-09-08 Smithkline Beecham Corporation Methode de traitement de l'asthme provoque par l'effort
EP1040831A2 (fr) 1999-04-02 2000-10-04 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
WO2000066590A2 (fr) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes
US6153619A (en) 1998-03-06 2000-11-28 American Cyanamid Company Aryl-substituted pyrimidines as insecticidal and acaricidal agents
WO2001004118A2 (fr) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Nouveaux derives de quinuclidine et compositions medicales les contenant
WO2001010143A1 (fr) 1999-07-28 2001-02-08 Motorola, Inc. Procede et appareil dans un systeme de communications sans fil conçu pour creer une fonction d'information
WO2001013953A2 (fr) 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Combinaison synergetique
WO2001016128A1 (fr) 1999-09-01 2001-03-08 Abbott Laboratories Dibenzopyranes utiles en tant qu'antagonistes du recepteur des glucocorticoides, dans le traitement du diabete
WO2001019322A2 (fr) 1999-09-17 2001-03-22 Smithkline Beecham Corporation Utilisation de csaids contre l'infection par rhinovirus
WO2001042193A1 (fr) 1999-12-08 2001-06-14 Theravance, Inc. Agonistes des recepteurs adrenergiques du beta 2
US6268310B1 (en) 1997-01-28 2001-07-31 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
US6321747B1 (en) 1997-01-08 2001-11-27 Smithkline Beecham Corporation Inhalation device
WO2002002565A2 (fr) 2000-07-05 2002-01-10 Abbott Laboratories Agents anti-inflammatoires a selectivite glucocortiocoide
WO2002026722A1 (fr) 2000-09-29 2002-04-04 Glaxo Group Limited Derives de morpholine-acetamide permettant de traiter les maladies inflammatoires
WO2002050021A1 (fr) 2000-12-21 2002-06-27 Glaxo Group Limited Sel phosphate inhibiteur d'oxyde nitrique synthase
WO2002059083A2 (fr) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Nouveaux composes
WO2002066422A1 (fr) 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2002070490A1 (fr) 2001-03-08 2002-09-12 Glaxo Group Limited Agonistes de beta-adrenocepteurs
WO2002076933A1 (fr) 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
WO2003008277A2 (fr) 2001-07-17 2003-01-30 Riverwood International Corporation Carton d'emballage dote d'un dispositif de distribution ameliore combine a une seule poignee
WO2003024439A1 (fr) 2001-09-14 2003-03-27 Glaxo Group Limited Derives de phenethanolamine destines au traitement de maladies respiratoires
US20030092712A1 (en) * 2000-12-20 2003-05-15 Doherty James B. (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003059899A1 (fr) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
WO2003061651A1 (fr) 2002-01-22 2003-07-31 The Regents Of The University Of California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
WO2003072539A1 (fr) 2002-02-28 2003-09-04 Glaxo Group Limited Derives de phenethanolamine pour traiter des maladies respiratoires
WO2003082280A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoiques, procedes de fabrication, compositions pharmaceutiques, et utilisations correspondants
WO2003082787A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
WO2003082827A1 (fr) 2002-04-02 2003-10-09 Schering Aktiengesellschaft Derives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
WO2003091204A1 (fr) 2002-04-25 2003-11-06 Glaxo Group Limited Derives de la phenethanolamine
WO2003101932A2 (fr) 2002-05-29 2003-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2003104195A1 (fr) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 4-(aryle ou heteroaryle)-2-butylamine et leur utilisation en tant que ligands de glucocorticoides
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2004009017A2 (fr) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
WO2004009016A2 (fr) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Compositions et procedes impliquant le site ii des recepteurs nucleaires d'hormones (nhr)
WO2004016578A2 (fr) 2002-07-25 2004-02-26 Glaxo Group Limited Composes medicamenteux
WO2004018429A2 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2004022547A1 (fr) 2002-09-06 2004-03-18 Glaxo Group Limited Derives de phenethanolamine, et leur utilisation pour le traitement des maladies respiratoires
WO2004026248A2 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
WO2004037773A1 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Derive de phenethanolamine utilise dans le traitement de maladies respiratoires
WO2004037807A2 (fr) 2002-10-22 2004-05-06 Glaxo Group Limited Composes medicinaux
WO2004037768A2 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Composes a usage medicinal
WO2004039762A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenethanolamine permettant de traiter des maladies des voies respiratoires
WO2004039766A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenylethanolamine pour le traitement de maladies respiratoires
WO2004073628A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Nouveaux composes

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25386A (en) 1859-09-13 Fastening fob
US2833779A (en) 1956-10-29 1958-05-06 American Cyanamid Co Substituted pyrazoles
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US3929807A (en) 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US3940486A (en) 1971-05-10 1976-02-24 Ciba-Geigy Corporation Imidazole derivatives in the treatment of pain
CA966134A (en) 1972-05-05 1975-04-15 Haydn W.R. Williams 1,8-naphthyridine compounds
US4058614A (en) 1973-12-04 1977-11-15 Merck & Co., Inc. Substituted imidazole compounds and therapeutic compositions therewith
US4199592A (en) 1978-08-29 1980-04-22 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-2-nitroimidazoles
JPS5618982A (en) 1979-06-14 1981-02-23 Wellcome Found Pyrimidine derivatives and medicinal drug containing them
GR75287B (fr) 1980-07-25 1984-07-13 Ciba Geigy Ag
GB2123831B (en) 1981-07-20 1986-01-15 Ciba Geigy Ag Trisubstituted oxazo compounds
US4503065A (en) 1982-08-03 1985-03-05 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl 1-2-halo imidazoles
JPS60226882A (ja) 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
US4565875A (en) 1984-06-27 1986-01-21 Fmc Corporation Imidazole plant growth regulators
US4560691A (en) 1984-07-13 1985-12-24 Sterling Drug Inc. 5-(Phenyl)-1,6-naphthyridin-2(1H)-ones, their cardiotonic use and preparation
US4686231A (en) 1985-12-12 1987-08-11 Smithkline Beckman Corporation Inhibition of 5-lipoxygenase products
IL83467A0 (en) 1986-08-15 1988-01-31 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for their preparation and pharmaceutical compositions containing the same
EP0278686A1 (fr) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines, leurs procédés de préparation et compositions pharmaceutiques les contenant
JPH01261306A (ja) 1988-04-13 1989-10-18 Nippon Kayaku Co Ltd ２−アルキルチオ−４−アミノピリミジン誘導体を有効成分とする開花促進剤
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
IE913473A1 (en) 1990-10-15 1992-04-22 Fujisawa Pharmaceutical Co Quinazoline derivatives and their preparation
JPH06502178A (ja) 1990-12-31 1994-03-10 藤沢薬品工業株式会社 イミダゾトリアジン誘導体
JP3375659B2 (ja) 1991-03-28 2003-02-10 テキサス インスツルメンツ インコーポレイテツド 静電放電保護回路の形成方法
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
IL102764A0 (en) 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
DE4131029A1 (de) * 1991-09-18 1993-07-29 Basf Ag Substituierte pyrido (2,3-d) pyrimidine als antidots
US5716972A (en) 1993-01-13 1998-02-10 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
US6008235A (en) 1992-01-13 1999-12-28 Smithkline Beecham Corporation Pyridyl substituted imidazoles
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
IL104369A0 (en) 1992-01-13 1993-05-13 Smithkline Beecham Corp Novel compounds and compositions
GB9303993D0 (en) 1993-02-26 1993-04-14 Fujisawa Pharmaceutical Co New heterocyclic derivatives
US5466692A (en) 1993-03-24 1995-11-14 American Home Products Corporation Substituted pyridopyrimidines and antihypertensives
US5593991A (en) 1993-07-16 1997-01-14 Adams; Jerry L. Imidazole compounds, use and process of making
US5670527A (en) 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
US5869043A (en) 1993-09-17 1999-02-09 Smithkline Beecham Corporation Drug binding protein
DE69421624T2 (de) 1993-09-17 2000-07-20 Smithkline Beecham Corp Medikamente bindendes protein
US5783664A (en) 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
US5426110A (en) 1993-10-06 1995-06-20 Eli Lilly And Company Pyrimidinyl-glutamic acid derivatives
EP1306377A3 (fr) 1993-11-08 2003-05-07 Smithkline Beecham Corporation Pyridyl-oxazoles et leur utilisation comme inhibiteurs de cytokines
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5559137A (en) 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
US5817670A (en) 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
JPH11507625A (ja) 1995-06-07 1999-07-06 アメリカン・ホーム・プロダクツ・コーポレイション ビフェニル誘導体の製造方法
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
US5760220A (en) 1995-06-07 1998-06-02 American Home Products Corporation Process for preparation of biphenyl derivatives
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
ZA9610687B (en) 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
NZ327044A (en) 1996-01-11 2000-01-28 Smithkline Beecham Corp Substituted imidazole compounds
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US20020137696A1 (en) 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
US6235760B1 (en) 1996-03-25 2001-05-22 Smithkline Beecham Corporation Treatment for CNS injuries
AU2521597A (en) 1996-04-12 1997-11-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyramidine derivatives
US6875769B2 (en) 1996-05-23 2005-04-05 Pfizer Inc. Substituted6,6-hetero-bicyclicderivatives
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
KR20000029843A (ko) * 1996-08-06 2000-05-25 디. 제이. 우드;스피겔 알렌 제이 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
US6509320B1 (en) 1996-10-16 2003-01-21 Icn Pharmaceuticals, Inc. Purine L-nucleosides, analogs and uses thereof
CZ126799A3 (cs) 1996-10-16 1999-07-14 Icn Pharmaceuticals Purinové L-nukleosidy a jejich analogy a farmaceutické prostředky, které je obsahují
US6455690B1 (en) 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5929076A (en) 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
JP2001509805A (ja) 1997-02-05 2001-07-24 ワーナー−ランバート・コンパニー 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン
US5945422A (en) * 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en) * 1997-02-05 2002-12-24 Warner-Lambert Company Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
US6362193B1 (en) 1997-10-08 2002-03-26 Smithkline Beecham Corporation Cycloalkenyl substituted compounds
US6423695B1 (en) 1998-01-13 2002-07-23 Ribapharm, Inc. Cytokine related treatments of disease
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
US20040044012A1 (en) 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6423425B1 (en) 1998-05-26 2002-07-23 Ppg Industries Ohio, Inc. Article having a chip-resistant electrodeposited coating and a process for forming an electrodeposited coating
ID27589A (id) 1998-05-26 2001-04-12 Warner Lambert Comapny Pirimidina bisiklik dan dihidropirimidina bisiklik 3,4 sebagai penghambat proliferasi selular
US6248225B1 (en) 1998-05-26 2001-06-19 Ppg Industries Ohio, Inc. Process for forming a two-coat electrodeposited composite coating the composite coating and chip resistant electrodeposited coating composition
JP2002517486A (ja) * 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
US5907465A (en) 1998-08-13 1999-05-25 Sensormatic Electronics Corporation Circuit for energizing EAS marker deactivation device with DC pulses of alternating polarity
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
JP2002526482A (ja) 1998-09-18 2002-08-20 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
WO2000020402A1 (fr) 1998-10-01 2000-04-13 Astrazeneca Ab Composes chimiques
WO2000023444A1 (fr) 1998-10-21 2000-04-27 Abbott Laboratories Composes de 4-aminopyrido[2,3-d]pyrimidine a disubstitution 5,7
WO2000024744A1 (fr) 1998-10-23 2000-05-04 F. Hoffmann-La Roche Ag Heterocycles d'azote bicycliques
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
WO2001001986A1 (fr) 1999-07-02 2001-01-11 Lipton Stuart A Procede pour reduire une blessure neuronale ou empecher l'apoptose
MXPA02002938A (es) 1999-09-17 2004-12-06 Abbott Gmbh & Co Kg Inhibidores de cinasa como agentes agentes terapeuticos.
AU2576501A (en) 1999-12-08 2001-06-18 Advanced Medicine, Inc. Protein kinase inhibitors
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
AP2002002586A0 (en) 2000-01-25 2002-09-30 Warner Lambert Co Pyrido[2,3-d] pyrimidine-2,7-diamine kinase inhibitors.
CZ20022521A3 (cs) 2000-01-27 2003-02-12 Warner-Lambert Company Pyridopyrimidinonové deriváty pro léčení neurodegenerativních onemocnění
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
IL151480A0 (en) 2000-03-06 2003-04-10 Warner Lambert Co 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors
AU2002248269A1 (en) 2000-10-19 2002-08-12 Smithkline Beecham Corporation Use of p38 inhibitors for the treatment of inflammation-enhanced cough
JP2002205986A (ja) 2000-11-08 2002-07-23 Takeda Chem Ind Ltd ピリミジン誘導体およびそれを含有する除草剤
US6945422B2 (en) * 2000-11-08 2005-09-20 Delphi Technologies, Inc. In-tank fuel line quick connector assembly
WO2002064096A2 (fr) 2001-02-16 2002-08-22 Tularik Inc. Procedes d'utilisation d'agents antiviraux a base de pyrimidine
DE10108481A1 (de) 2001-02-22 2002-10-24 Bayer Ag Pyridylpyrimidine
US7105667B2 (en) 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
WO2002088079A2 (fr) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
HUP0402352A2 (hu) 2001-06-19 2005-02-28 Bristol-Myers Squibb Co. Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
JP4178783B2 (ja) 2001-10-19 2008-11-12 三菱化学株式会社 光学記録媒体
US7019002B2 (en) 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
ATE314370T1 (de) * 2002-01-22 2006-01-15 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one
CA2484921A1 (fr) 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Derives nucleosidiques destines au traitement de l'infection par le virus de l'hepatite c
ITBO20020304A1 (it) 2002-05-17 2003-11-17 Magneti Marelli Powertrain Spa Nuovi condotti in materiale polimerico
TW200409629A (en) * 2002-06-27 2004-06-16 Bristol Myers Squibb Co 2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
TW200413381A (en) * 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
US7384937B2 (en) 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
JP2004203751A (ja) 2002-12-24 2004-07-22 Pfizer Inc 置換６，６−ヘテロ二環式誘導体
JP2006516561A (ja) 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
CA2527017A1 (fr) 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines et pyrido[3,4-d] pyrimidines utilises comme inhibiteurs de recepteurs tyrosine kinase
CN1894222A (zh) 2003-08-05 2007-01-10 沃泰克斯药物股份有限公司 作为电压门控离子通道抑制剂的稠合嘧啶化合物
DE102004020908A1 (de) 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
PE20100737A1 (es) 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
PE20100741A1 (es) 2005-03-25 2010-11-25 Glaxo Group Ltd COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
EP1868612A4 (fr) 2005-03-25 2010-03-24 Glaxo Group Ltd Nouveaux composes
WO2006127678A2 (fr) 2005-05-23 2006-11-30 Smithkline Beecham Corporation Inhibition de la marque p38 destinee au traitement de l'obesite
EP1931667A1 (fr) * 2005-09-28 2008-06-18 Ranbaxy Laboratories Limited Dérivés de pyrido-pyrimidine pouvant être employés en tant qu'agents anti-inflammatoires
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
PE20070823A1 (es) * 2005-11-15 2007-08-09 Glaxo Group Ltd Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
WO2007076085A2 (fr) * 2005-12-22 2007-07-05 Prolexys Pharmaceuticals, Inc . Pyrimidones et thiopyrimidones fusionnees et leurs utilisations
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
EP2086975B1 (fr) * 2006-11-20 2012-03-14 Bristol-Myers Squibb Company 7,8-dihydro-1,6-naphthyridin-5(6h)-ones et composés bicycliques apparentés comme inhibiteurs de la dipeptidyl peptidase iv et procédés
CN102015704A (zh) * 2008-04-29 2011-04-13 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂

Patent Citations (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918408A (en) 1957-04-08 1959-12-22 Lakeside Lab Inc Anti-spasmodic compositions specific for treating spasm of the colon
US3631045A (en) 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3910913A (en) 1969-11-04 1975-10-07 American Home Prod 4,5-Diamino-7H-pyrrolo{8 2,3-d{9 pyrimidine derivatives
GB2064336A (en) 1979-12-06 1981-06-17 Glaxo Group Ltd Device for dispensing medicaments
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
EP0069715A1 (fr) 1981-07-08 1983-01-12 Aktiebolaget Draco Inhalateur de poudre
GB2129691A (en) 1982-10-08 1984-05-23 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265A (en) 1982-10-08 1986-07-09 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2178965A (en) 1985-07-30 1987-02-25 Glaxo Group Ltd Devices for administering medicaments to patients
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
US5035237A (en) 1985-07-30 1991-07-30 Newell Robert E Devices for administering medicaments to patients
GB2242134A (en) 1990-03-02 1991-09-25 Glaxo Group Ltd Inhalation device
US5590645A (en) 1990-03-02 1997-01-07 Glaxo Group Limited Inhalation device
US5860419A (en) 1990-03-02 1999-01-19 Glaxo Group Limited Inhalation device
US5873360A (en) 1990-03-02 1999-02-23 Glaxo Group Limited Inhalation device
US5468751A (en) 1990-08-10 1995-11-21 Ciba-Geigy Corporation Aminopyrimidine derivatives as microbicides, insecticides and acaricides
US5474996A (en) 1991-05-23 1995-12-12 Roussel Uclaf Pyrimidine derivatives
WO1993013055A1 (fr) 1991-12-24 1993-07-08 The Wellcome Foundation Limited Derives d'amidino et leur utilisation comme inhibiteurs de synthase d'oxyde nitrique
US5552438A (en) 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
WO1995034534A1 (fr) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Inhibiteurs d'enzymes
US5772085A (en) 1995-03-10 1998-06-30 Minnesota Mining And Manufacturing Free flow aerosol valves
US5998428A (en) 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
WO1997032583A1 (fr) 1996-03-08 1997-09-12 Smithkline Beecham Corporation Utilisations de composes csaidtm en tant qu'inhibiteurs de l'angiogenese
WO1997035856A1 (fr) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Nouveau traitement des lesions du systeme nerveux central
US6321747B1 (en) 1997-01-08 2001-11-27 Smithkline Beecham Corporation Inhalation device
WO1998030537A1 (fr) 1997-01-13 1998-07-16 Glaxo Group Limited Inhibiteurs de monoxyde d'azote synthetase
US6268310B1 (en) 1997-01-28 2001-07-31 Nippon Soda Co., Ltd. Oxazole derivative, process for producing the same, and herbicide
WO1998054159A1 (fr) 1997-05-30 1998-12-03 Schering Aktiengesellschaft Acylanilides non steroidiques heterocycliquement substitues a effet mixte gestagene et androgene
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
WO1999032121A1 (fr) 1997-12-19 1999-07-01 Smithkline Beecham Corporation .0mposes d'imidazole heteroaryle substitues, leurs compositions et usages pharmaceutiques
WO1999041253A1 (fr) 1998-02-17 1999-08-19 Tularik Inc. Antiviraux derives de pyrimidine
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
US6153619A (en) 1998-03-06 2000-11-28 American Cyanamid Company Aryl-substituted pyrimidines as insecticidal and acaricidal agents
WO1999047505A1 (fr) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteurs de pde iii/iv a base de phtalazinones
WO1999062875A1 (fr) 1998-05-30 1999-12-09 Glaxo Group Limited Inhibiteurs de synthase d'oxyde nitrique
WO2000051599A1 (fr) 1999-03-01 2000-09-08 Smithkline Beecham Corporation Methode de traitement de l'asthme provoque par l'effort
EP1040831A2 (fr) 1999-04-02 2000-10-04 Pfizer Products Inc. Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
WO2000066590A2 (fr) 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Composes modulateurs de recepteur de progesterone tetracycliques et procedes
WO2001004118A2 (fr) 1999-07-14 2001-01-18 Almirall Prodesfarma S.A. Nouveaux derives de quinuclidine et compositions medicales les contenant
WO2001010143A1 (fr) 1999-07-28 2001-02-08 Motorola, Inc. Procede et appareil dans un systeme de communications sans fil conçu pour creer une fonction d'information
WO2001013953A2 (fr) 1999-08-21 2001-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh Combinaison synergetique
WO2001016128A1 (fr) 1999-09-01 2001-03-08 Abbott Laboratories Dibenzopyranes utiles en tant qu'antagonistes du recepteur des glucocorticoides, dans le traitement du diabete
WO2001019322A2 (fr) 1999-09-17 2001-03-22 Smithkline Beecham Corporation Utilisation de csaids contre l'infection par rhinovirus
WO2001042193A1 (fr) 1999-12-08 2001-06-14 Theravance, Inc. Agonistes des recepteurs adrenergiques du beta 2
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
WO2002002565A2 (fr) 2000-07-05 2002-01-10 Abbott Laboratories Agents anti-inflammatoires a selectivite glucocortiocoide
WO2002026722A1 (fr) 2000-09-29 2002-04-04 Glaxo Group Limited Derives de morpholine-acetamide permettant de traiter les maladies inflammatoires
WO2002059083A2 (fr) * 2000-10-23 2002-08-01 Smithkline Beecham Corporation Nouveaux composes
US20030092712A1 (en) * 2000-12-20 2003-05-15 Doherty James B. (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
US6809199B2 (en) 2000-12-20 2004-10-26 Merck & Co., Inc. (Halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
WO2002050021A1 (fr) 2000-12-21 2002-06-27 Glaxo Group Limited Sel phosphate inhibiteur d'oxyde nitrique synthase
WO2002066422A1 (fr) 2001-02-14 2002-08-29 Glaxo Group Limited Derives de phenethanolamine pour le traitement de maladies respiratoires
WO2002070490A1 (fr) 2001-03-08 2002-09-12 Glaxo Group Limited Agonistes de beta-adrenocepteurs
WO2002076933A1 (fr) 2001-03-22 2002-10-03 Glaxo Group Limited Derives formanilides utilises en tant qu'agonistes de l'adrenorecepteur beta2
WO2003008277A2 (fr) 2001-07-17 2003-01-30 Riverwood International Corporation Carton d'emballage dote d'un dispositif de distribution ameliore combine a une seule poignee
WO2003024439A1 (fr) 2001-09-14 2003-03-27 Glaxo Group Limited Derives de phenethanolamine destines au traitement de maladies respiratoires
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003059899A1 (fr) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoides, procedes de fabrication, preparations pharmaceutiques renfermant ces mimetiques et utilisations
WO2003061651A1 (fr) 2002-01-22 2003-07-31 The Regents Of The University Of California Ligands non steroidiens pour le recepteur des corticoides, compositions et utilisations desdits ligands
WO2003072539A1 (fr) 2002-02-28 2003-09-04 Glaxo Group Limited Derives de phenethanolamine pour traiter des maladies respiratoires
WO2003082787A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
WO2003082280A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques de glucocorticoiques, procedes de fabrication, compositions pharmaceutiques, et utilisations correspondants
WO2003082827A1 (fr) 2002-04-02 2003-10-09 Schering Aktiengesellschaft Derives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
WO2003086294A2 (fr) 2002-04-11 2003-10-23 Merck & Co., Inc. Derives de 1h-benzo[f]indazol-5-yl utilises en tant que modulateurs selectifs du recepteur glucocorticoide
WO2003091204A1 (fr) 2002-04-25 2003-11-06 Glaxo Group Limited Derives de la phenethanolamine
WO2003101932A2 (fr) 2002-05-29 2003-12-11 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2003104195A1 (fr) 2002-06-06 2003-12-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de 4-(aryle ou heteroaryle)-2-butylamine et leur utilisation en tant que ligands de glucocorticoides
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
WO2004009017A2 (fr) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
WO2004009016A2 (fr) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Compositions et procedes impliquant le site ii des recepteurs nucleaires d'hormones (nhr)
WO2004016578A2 (fr) 2002-07-25 2004-02-26 Glaxo Group Limited Composes medicamenteux
WO2004018429A2 (fr) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Composes mimetiques de glucocorticoide, leurs procedes de fabrication, compositions pharmaceutiques, et leurs utilisations
WO2004022547A1 (fr) 2002-09-06 2004-03-18 Glaxo Group Limited Derives de phenethanolamine, et leur utilisation pour le traitement des maladies respiratoires
WO2004026248A2 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
WO2004037807A2 (fr) 2002-10-22 2004-05-06 Glaxo Group Limited Composes medicinaux
WO2004037773A1 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Derive de phenethanolamine utilise dans le traitement de maladies respiratoires
WO2004037768A2 (fr) 2002-10-28 2004-05-06 Glaxo Group Limited Composes a usage medicinal
WO2004039762A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenethanolamine permettant de traiter des maladies des voies respiratoires
WO2004039766A1 (fr) 2002-11-01 2004-05-13 Glaxo Group Limited Derives de phenylethanolamine pour le traitement de maladies respiratoires
WO2004073628A2 (fr) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Nouveaux composes

Non-Patent Citations (63)

* Cited by examiner, † Cited by third party
Title
"ACS Style Guide", 1986, AMERICAN CHEMICAL SOCIETY
"Principles and Practice", vol. 1, article "Burger's Medicinal Chemistry and Drug Discovery"
BADGER ET AL., ARTHRITIS RHEUM., vol. 43, 2000, pages 175 - 183
BADGER ET AL., CIRC. SHOCK, vol. 27, 1989, pages 51 - 61
BADGER ET AL., J. PHARM. EXP. THERA., vol. 279, no. 3, 1996, pages 1453 - 1461
BARVIAN ET AL., J. MED. CHEM., 2000, pages 4606 - 4616
BEDAIWY ET AL., HUMAN REPRODUCTION, vol. 17, 2002, pages 426 - 431
BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19
BOEHM ET AL., JOURNAL OFMEDICINAL CHEMISTRY, vol. 39, 1996, pages 3929 - 3937
BOSCHELLIAT ET AL., J. MED. CHEM., 1998, pages 4365 - 4377
CARTER, AB ET AL., J BIOL CHEM, vol. 274, 1999, pages 30858 - 63
CHEM PHARM BULL., 1987, pages 4972 - 4976
CIRCULATION, vol. 107, 2003, pages 1514 - 1519
CIRCULATION, vol. 107, 2003, pages 363 - 369
COHEN, P., TRENDS CELL BIOL., 1997, pages 353 - 361
COLOTTA ET AL., J IMMUNOL, vol. 132, 1984, pages 936
D. FLEISHER; S. RAMON; H. BARBRA: "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", ADVANCED DRUG DELIVERY REVIEWS, vol. 19, no. 2, 1996, pages 115 - 130, XP002478093, DOI: doi:10.1016/0169-409X(95)00103-E
DINARELLO ET AL., REV. INFECT. DISEASE, vol. 6, 1984, pages 51
DINARELLO, J. CLINICAL IMMUNOLOGY, 1985, pages 287 - 297
EDWARD B. ROCHE,: "Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
ELISA, OLIVERA ET AL., CIRC. SHOCK, vol. 37, 1992, pages 301 - 306
GALLAGHER ET AL.: "Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSBP Kinase", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, 1997, pages 49 - 64
GREENE ET AL.: "Protecting Groups in Organic Synthesis(2nd edition, )", 1991, JOHN WILEY & SONS
GRISWOLD ET AL., ARTHRITIS RHEUM., vol. 31, 1988, pages 1406 - 1412
GRISWOLD ET AL., DRUGS UNDER EXP. AND CLINICAL RES., vol. XIX, no. 6, 1993, pages 243 - 248
GRISWOLD ET AL., PHARMACOL. COMM., vol. 7, 1996, pages 323 - 229
GRUNBERG ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 156, 1997, pages 609
HANAFUSA ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 27161 - 27167
HOFGEN, N., 15TH EFMC INT. SYMP. MED. CHEM., 6 September 1998 (1998-09-06), pages 98
HUNTER, T.: "Methods in Enzvrnology", vol. 200, 1991, ACADEMIC PRESS, pages: 3
JACKSON ET AL., J. PHARMACOL. EXP. THER., vol. 284, 1998, pages 687 - 692
JACOBSEN ET AL., TETRAHEDRON, 1994, pages 4323 - 34
KUMAR, S., NATURE REV. DRUG DISCOVERY, vol. 2, 2003, pages 717
KYRIAKIS, JM; AVRUCH, J., PHVSIOL REV, vol. 81, 2001, pages 807 - 869
LANDELLS, L.J. ET AL., EUR RESP J, vol. 12, no. 28, 19 September 1998 (1998-09-19), pages 2393
LAPING ET AL., MOLEC. PHARMACOL., vol. 62, 2002, pages 58 - 64
LEE ET AL., B ANN. N. Y. ACAD. SCI., vol. 696, 1993, pages 149 - 170
LEE ET AL., INT. J. IMMUNOPHARMAC., vol. 10, no. 7, 1988, pages 835
LEE ET AL., NATURE, vol. 300, no. 72, December 1994 (1994-12-01), pages 639 - 746
LEE ET AL.: "Annals N. Y. Acad. Sci.", vol. 696, 1993, pages: 149
LEE, J. C. ET AL., PHARMACOL. THER., vol. 82, no. 2-3, 1999, pages 389 - 397
MARSHALL, J. C., CELL, vol. 80, 1995, pages 179 - 278
MATYUS ET AL., HETEROCYCLES, 1985, pages 2057 - 64
MORIN; HUOT, CANCER RESEARCH, vol. 64, 2004, pages 1893 - 1898
ONO, K.; HAN, J., CELLULAR SIGNALLING, vol. 12, 2000, pages 1 - 13
PLATANIAS, PHARMACOL. THERAP., vol. 98, 2003, pages 129 - 142
SACCINI, S., NATURE IMMUNOL., vol. 3, 2002, pages 69 - 75
SANTILLI ET AL., J. HETEROCYCL. CHEM., 1971, pages 445 - 53
SANTILLI, J. HETEROCYCL. CHEM., 1971, pages 445 - 53
SIDWELL ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 36, 1992, pages 473 - 476
SOLBERG, J.; UNDHEIM, K., ACTA CHEMICA SCANDINAVIA, 1989, pages 62 - 68
STILL ET AL., TETRAHEDRON LETT., 1983, pages 4405 - 8
SUBAUSTE ET AL., J. CLIN. INVEST., vol. 96, 1995, pages 549
T. HIGUCHI; V. STELLA: "Prodrugs as Novel Delivery Systems", vol. 14, A.C.S. SYMPOSIUM SERIES
TANABE SEIYAKU; FUJI, K. ET AL., J PHARMACOL EXP THER, vol. 284, no. 1, 1998, pages 162
TEREN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 155, 1997, pages 1362
TUMKEVICIUS, S., LIEBIGS ANN., 1995, pages 1703 - 1705
TURNER ET AL., CLIN. INFEC. DIS., vol. 26, 1998, pages 840
UNDERWOOD ET AL., J. PHARMACOL. EXP. THER., vol. 293, 2000, pages 281 - 288
VOTTA ET AL., IN VITRO. BONE, vol. 15, 1994, pages 533 - 538
WITZ, FERTILITY AND STERILITY, vol. 73, 2000, pages 212 - 214
YOO ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 43001 - 43007
ZHU ET AL., J CLIN. INVEST, vol. 97, 1996, pages 421

Also Published As

Publication number Publication date
CN102746299A (zh) 2012-10-24
KR101235497B1 (ko) 2013-02-20
CN101258148A (zh) 2008-09-03
MY145343A (en) 2012-01-31
ZA200707564B (en) 2008-10-29
EP1868611A4 (fr) 2009-05-27
TWI389690B (zh) 2013-03-21
WO2006104915A2 (fr) 2006-10-05
PE20100737A1 (es) 2010-11-27
JP5037487B2 (ja) 2012-09-26
AR053346A1 (es) 2007-05-02
NO20075275L (no) 2007-12-27
CA2602553A1 (fr) 2006-10-05
EP2447266B1 (fr) 2013-06-12
CN102746301A (zh) 2012-10-24
US20090069318A1 (en) 2009-03-12
WO2006104915A9 (fr) 2008-01-03
PE20061351A1 (es) 2007-01-14
US7678801B2 (en) 2010-03-16
KR20070113255A (ko) 2007-11-28
ES2426251T3 (es) 2013-10-22
TW200714281A (en) 2007-04-16
SG166771A1 (en) 2010-12-29
BRPI0609437A2 (pt) 2010-04-06
WO2006104915A3 (fr) 2007-11-22
IL185870A (en) 2013-06-27
EA012875B1 (ru) 2009-12-30
JP2008534513A (ja) 2008-08-28
UY29440A1 (es) 2006-10-02
MX2007011856A (es) 2007-10-10
MA29341B1 (fr) 2008-03-03
US8207176B2 (en) 2012-06-26
IL185870A0 (en) 2008-01-06
AU2006229993B2 (en) 2011-05-19
NZ561237A (en) 2011-02-25
EA200702071A1 (ru) 2008-02-28
HK1111422A1 (fr) 2008-08-08
CA2602553C (fr) 2013-04-30
ES2398246T3 (es) 2013-03-14
UA95444C2 (ru) 2011-08-10
EP1868611A2 (fr) 2007-12-26
US20060235029A1 (en) 2006-10-19
CN102746300A (zh) 2012-10-24
MY145281A (en) 2012-01-13
AU2006229993A1 (en) 2006-10-05
US8354416B2 (en) 2013-01-15
EP2436686A1 (fr) 2012-04-04
EP1868611B1 (fr) 2012-11-14
US20090156597A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US8207176B2 (en) Compounds
US7674789B2 (en) Compounds
US7423042B2 (en) Compounds
US20100144755A1 (en) Novel Compounds
US20090318424A1 (en) Novel compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110802

AC Divisional application: reference to earlier application

Ref document number: 1868611

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101ALI20121213BHEP

Ipc: A61P 19/02 20060101ALI20121213BHEP

Ipc: A61P 19/00 20060101ALI20121213BHEP

Ipc: C07D 487/04 20060101AFI20121213BHEP

Ipc: A61P 29/00 20060101ALI20121213BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXO GROUP LIMITED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1868611

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 616647

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006036827

Country of ref document: DE

Effective date: 20130808

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2426251

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20131022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130913

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 616647

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130612

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130612

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131014

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131012

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

26N No opposition filed

Effective date: 20140313

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20140225

Year of fee payment: 9

Ref country code: ES

Payment date: 20140325

Year of fee payment: 9

Ref country code: TR

Payment date: 20140225

Year of fee payment: 9

Ref country code: IT

Payment date: 20140318

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006036827

Country of ref document: DE

Effective date: 20140313

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20140225

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20140324

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140331

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140324

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140324

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140331

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602006036827

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150324

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20151130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150324

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150325

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060324

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150324